


10031180 080502  
JC10 Rec'd PCT/PTO 16 JAN 2002

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER A0000096-01-SMH	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
				10/031180	
INTERNATIONAL APPLICATION NO. PCT/US00/18347		INTERNATIONAL FILING DATE 5 July 2000		PRIORITY DATE CLAIMED July 16, 1999	
TITLE OF INVENTION Method for Treating Chronic Pain Using Mek Inhibitors					
APPLICANT(S) FOR DO/EO/US DIXON, Alistair, LEE, Kevin, PINNOCK, Robert Denham					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application, as filed (35 U.S.C. 371(c)(2)).</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto.</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p><b>Items 11 to 20 below concern document(s) or information included:</b></p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information:  International Search Report (PCT/ISA/210)  International Preliminary Examination Report (PCT/IPEA/409)  Certificate of Mailing by Express Mail</p>					

Express Mail No. EF378128688US  
PD-A0000096-01-SMH

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) <b>10/031180</b>		INTERNATIONAL APPLICATION NO. PCT/US00/18347		ATTORNEY'S DOCKET NUMBER A0000096-01-SMH																															
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. .... <b>\$1000.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$860.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$710.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$690.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b>  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>																															
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	860.00																														
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:20%;">\$</th> <th style="width:20%;"></th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>53 - 20 =</td> <td>33</td> <td>x \$18.00</td> <td>\$</td> <td>594.00</td> </tr> <tr> <td>Independent claims</td> <td>2 - 3 =</td> <td></td> <td>x \$80.00</td> <td>\$</td> <td>0.00</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+</td> <td>\$270.00</td> </tr> <tr> <td colspan="4"><b>TOTAL OF ABOVE CALCULATIONS =</b></td> <td>\$</td> <td>1,584.00</td> </tr> </tbody> </table>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$		Total claims	53 - 20 =	33	x \$18.00	\$	594.00	Independent claims	2 - 3 =		x \$80.00	\$	0.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+	\$270.00	<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	1,584.00	\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																															
Total claims	53 - 20 =	33	x \$18.00	\$	594.00																														
Independent claims	2 - 3 =		x \$80.00	\$	0.00																														
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+	\$270.00																														
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	1,584.00																														
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	+																														
<b>SUBTOTAL =</b>				\$																															
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$																															
<b>TOTAL NATIONAL FEE =</b>				\$	1,584.00																														
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$																															
<b>TOTAL FEES ENCLOSED =</b>				\$	1,584.00																														
				Amount to be refunded:	\$																														
				charged:	\$																														
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.  b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>23-0455</u> in the amount of \$ <u>1,584.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.  c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0455</u> . A duplicate copy of this sheet is enclosed.  d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card          information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.																																			
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR          1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b>																																			
SEND ALL CORRESPONDENCE TO: Suzanne M. Harvey Warner-Lambert Company Patent Department 2800 Plymouth Road Ann Arbor, Michigan 48105 Telephone: (734) 622-2658 Facsimile: (734) 622-1553																																			
				 SIGNATURE  Suzanne M. Harvey NAME  42,640 REGISTRATION NUMBER																															

**METHOD FOR TREATING CHRONIC PAIN  
USING MEK INHIBITORS**

5

**BACKGROUND**

The invention features a method for treating chronic pain using MEK inhibitors. Chronic pain includes neuropathic pain, and chronic inflammatory pain.

10

Abnormality anywhere in a nerve pathway disrupts nerve signals, which in turn are abnormally interpreted in the brain, causing neuropathic pain. Neuropathic pain may be, for example, a deep ache, a burning sensation, or hypersensitivity to touch. Diseases or conditions associated with neuropathic pain include, without limitation, diabetic neuropathy, causalgia, plexus avulsion, neuroma, vasculitis, crush injury, viral infections (e.g., herpes virus infection or HIV), constriction injury, tissue injury, nerve injury from the periphery to the central nervous system, limb amputation, hypothyroidism, uremia, chronic alcoholism, post-operative pain, arthritis, back pain, and vitamin deficiencies.

20

Infections such as herpes zoster (shingles) can cause nerve inflammation and produce postherpetic neuralgia, a chronic burning localized to the area of viral infection. Hyperalgesia is when an already noxious stimulus becomes more painful, and allodynia, when a previously non-noxious stimulus becomes painful (such as contact of clothing or a breeze). Reflex sympathetic dystrophy is accompanied by swelling and sweating or changes in local blood flow, tissue atrophy, or osteoporosis. Causalgia, including severe burning pain and swelling, sweating, and changes in blood flow, may follow an injury or disease of a major nerve such as the sciatic nerve. Some types of chronic low back pain can have a neuropathic component (e.g., sciatica, postpoliomyelitis and CPRM). Neuropathic pain may also be induced by cancer or chemotherapy.

30

Neuropathic pain is currently treated with anticonvulsants such as carbamazepine and antidepressants such as amitriptyline. NSAIDs and opioids generally have little effect (*Fields et al 1994 Textbook of Pain p 991-996 (pub: Churchill Livingstone), James & Page 1994*

5 *J.Am.Pediatr.Med.Assoc, 8: 439-447, Galer, 1995 Neurology 45 S17-S25.*


Neuropathic conditions that have been treated with gabapentin include: postherpetic neuralgia, postpoliomyelitis, CPRM, HIV-related neuropathy, trigeminal neuralgia, and reflex sympathetic dystrophy (RSD).

The generally weak efficacy of antiinflammatory agents suggests that the  
10 mechanism for chronic pain is separate from hyperalgesia.

### SUMMARY OF THE INVENTION

The invention features a method for treating chronic pain, which  
15 method includes the step of administering a composition including a MEK inhibitor to a patient in need of such treatment. Chronic pain includes neuropathic pain, idiopathic pain, and pain associated with vitamin deficiencies, uremia, hypothyroidism post-operative pain, arthritis, back pain, and chronic alcoholism. The invention also features compounds as disclosed,  
20 formulated for the treatment of chronic pain. Such a composition may include one or more MEK inhibitor compounds having a structure disclosed in patent applications PCT/US98/13106, international filing date June 24, 1998, and PCT/US98/13105, international filing date June 24, 1998.

Examples of MEK inhibitors include 4-bromo and 4-iodo phenylamino  
25 benzhydroxamic acid derivatives which are kinase inhibitors and as such are useful for treating proliferative diseases such as cancer, psoriasis, and restenosis. The compounds are defined by Formula I



WO 01/05392

PCT/US00/18347

wherein:

R<sub>1</sub> is hydrogen, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, trifluoromethyl, or CN;

R<sub>2</sub> is hydrogen;

- 5 R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> independently are hydrogen, hydroxy, halo, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, nitro, CN, or (O or NH)<sub>m</sub>-(CH<sub>2</sub>)<sub>n</sub>-R<sub>9</sub>, where R<sub>9</sub> is hydrogen, hydroxy, CO<sub>2</sub>H or NR<sub>10</sub>R<sub>11</sub>;

n is 0 to 4;

m is 0 or 1;


- 10 R<sub>10</sub> and R<sub>11</sub> independently are hydrogen or C<sub>1</sub>-C<sub>8</sub> alkyl, or taken together with the nitrogen to which they are attached can complete a 3- to 10-member cyclic ring optionally containing one, two, or three additional heteroatoms selected from O, S, NH, or N-C<sub>1</sub>-C<sub>8</sub> alkyl;

- 15 
$$\begin{array}{c} \text{O} \\ \parallel \\ \text{R}_6 \end{array}$$
 R<sub>6</sub> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C-C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, aralkyl, or C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

- R<sub>7</sub> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>3</sub>-C<sub>10</sub> (cycloalkyl or cycloalkyl optionally containing a heteroatom selected from O, S, or NR<sub>9</sub>); or R<sub>6</sub> and R<sub>7</sub> taken together with the N-O to which they are attached can complete a 5- to 10-membered cyclic ring, optionally containing one, two, or three additional heteroatoms selected from O, S, or NR<sub>10</sub>R<sub>11</sub>;
- 20


- and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups can be unsubstituted or substituted by cycloalkyl (or cycloalkyl optionally containing a heteroatom selected from O, S, or NR<sub>9</sub>), aryl, aryloxy, heteroaryl, or heteroaryloxy.
- 25

Preferred compounds have Formula II



where  $R_1$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ , and  $R_7$  are as defined above. Especially preferred are compounds wherein  $R_1$  is methyl or halo, and  $R_3$ ,  $R_4$ , and  $R_5$  are halo such as fluoro or bromo.

Another preferred group of compounds have Formula III







wherein  $R_1$ ,  $R_3$ ,  $R_4$ ,  $R_5$ , and  $R_7$  are as defined above.

The most preferred compounds are those wherein  $R_1$  is methyl or halo such as F, Br, Cl, and I,  $R_3$  is hydrogen or halo such as fluoro,  $R_4$  is halo such as fluoro, and  $R_5$  is hydrogen or halo such as fluoro or bromo. Such compounds have the formulas

WO 01/05392

PCT/US00/18347



Specific compounds provided by the invention include the following:

3,4,5-Trifluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Chloro-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-

5 benzamide;

5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-

benzamide;

N-Hydroxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide;

3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;

10 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-  
benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-

benzamide;

2-(2-Fluoro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;

15 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;

5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-

benzamide;

5-Bromo-2-(2-bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-

benzamide;

20 2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-methyl-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;

- 2-(2-Bromo-4-iodo-phenylamino)-5-chloro-3,4-difluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;
- 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
- 5 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- 10 N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;
- 15 N-Cyclopropylmethoxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide;
- N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;
- 20 5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;
- 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;
- N-Cyclopropylmethoxy-2-(2-fluoro-4-iodo-phenylamino)-4-nitro-benzamide;
- 25 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;
- 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;
- 30 5-Bromo-2-(2-bromo-4-iodo-phenylamino)-N-ethoxy-3,4-difluoro-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-N-ethoxy-4-nitro-benzamide;



WO 01/05392

PCT/US00/18347

- 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-5-chloro-N-cyclopropylmethoxy-3,4-difluoro-benzamide
- 5 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-nitro-benzamide;
- N-Cyclopropylmethoxy-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;
- N-Cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-
- 10 benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;
- 15 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;
- 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-isopropyl-
- 20 benzamide;
- N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide;
- 25 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;
- 3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide
- 30 (HCl salt);
- 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide;

3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)-3,4-difluoro-benzamide monohydrochloride salt;

5 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;


5-Bromo-N-cyclohexylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-N-cyclopentylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide; and

15 5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide.

Other aspects of the invention are provided in the description, examples and claims below.

Further examples of MEK inhibitors include 4-bromo and 4-iodo phenylamino benzoic acid derivatives which are selective MEK kinase inhibitors. The compounds are defined by Formula I(A)



wherein:

R<sub>1</sub> is hydrogen, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, trifluoromethyl, or  
25 CN;

R<sub>2</sub> is hydrogen;

WO 01/05392

PCT/US00/18347

R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> independently are hydrogen, hydroxy, halo, trifluoromethyl,  
C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, nitro, CN, or -(O or NH)<sub>m</sub>-(CH<sub>2</sub>)<sub>n</sub>-R<sub>9</sub>,  
where R<sub>9</sub> is hydrogen, hydroxy, CO<sub>2</sub>H, or NR<sub>10</sub>R<sub>11</sub>;

n is 0-4;

5 m is 0 or 1;

R<sub>10</sub> and R<sub>11</sub> independently are hydrogen or C<sub>1</sub>-C<sub>8</sub> alkyl, or taken together  
with the nitrogen to which they are attached, can complete a  
3-10 member cyclic ring optionally containing one, two, or three  
additional heteroatoms selected from O, S, NH, or N-C<sub>1</sub>-C<sub>8</sub> alkyl;

10 Z is COOR<sub>7</sub>, tetrazolyl, CONR<sub>6</sub>R<sub>7</sub>, CONHNR<sub>10</sub>R<sub>11</sub>, or CH<sub>2</sub>OR<sub>7</sub>;


R<sub>6</sub> and R<sub>7</sub> independently are hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl,

O

15 C<sub>2</sub>-C<sub>8</sub> alkynyl, C - C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, heteroaryl,  
C<sub>3</sub>-C<sub>10</sub> cycloalkyl, or C<sub>3</sub>-C<sub>10</sub> (cycloalkyl optionally containing  
one, two, or three heteroatoms selected from O, S, NH, or N  
alkyl); or R<sub>6</sub> and R<sub>7</sub> together with the nitrogen to which they are  
attached complete a 3-10 member cyclic ring optionally  
containing 1, 2, or 3 additional heteroatoms selected from O, S,  
20 NH, or N alkyl;

and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups can be  
unsubstituted or substituted by halo, hydroxy, alkoxy, amino,  
alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, heteroaryl, or  
heteroaryloxy, and the pharmaceutically acceptable salts thereof.

25 Preferred compounds have Formula II(A)




II(A)

WO 01/05392


PCT/US00/18347

where R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>7</sub> are as defined above. Especially preferred are compounds wherein R<sub>1</sub> is methyl or halo, and R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are halo such as fluoro or bromo.


- 5 The compounds of Formula II(A) are carboxylic acids when R<sub>7</sub> is hydrogen, and are esters when R<sub>7</sub> is other than hydrogen. Compounds which are analogous to the acids in physical and biological properties are tetrazolyl derivatives of Formula IIa



IIa



Another preferred group of compounds are amides Formula III(A)




III(A)


WO 01/05392

PCT/US00/18347





and hydrazides of Formula IIIa



The benzyl alcohols of the invention have Formula IV(A)



- 5 Among this group, the most preferred compounds are those wherein  $R_1$  is methyl,  $R_3$  is hydrogen or halo such as fluoro,  $R_4$  is halo such as fluoro, and  $R_5$  is hydrogen or halo such as fluoro, bromo, or chloro. Representative compounds have the formulas



Preferred embodiments for this invention include methods using one or more of the following compounds:

(a) said MEK inhibitor has a structure selected from:

- 5           2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-  
            benzamide;  
            N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-  
            benzamide;  
            N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-  
10           benzamide, potassium salt;  
            2-(2-Chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-3,4-difluoro-  
            benzamide;  
            2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-  
            benzamide;  
15           5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-  
            benzamide;  
            3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
            5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-  
            benzamide;  
20           5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-  
            benzamide;  
            N-Cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-  
            benzamide;  
            5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-  
25           phenylamino)-benzamide;  
            5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-  
            phenylamino)-benzamide;  
            5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-  
            phenylamino)-benzamide;  
30           5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-  
            difluoro-benzamide;  
            4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

- 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide,  
hydrochloride salt;
- 5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;
- 5 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)-  
benzamide;
- 3,4-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;
- 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-  
propoxy)-benzamide;
- 10 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-propoxy)-  
benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-[2-(2-methoxy-  
ethoxy)-ethoxy]-benzamide;
- 15 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-propoxy)-  
benzamide;
- 5-Bromo-3,4-difluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-  
phenylamino)-benzamide;
- 3,4,5-Trifluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-  
phenylamino)-benzamide;
- 20 3,4,5-Trifluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)-  
benzamide; and
- 25 3,4-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;
- (b) said MEK inhibitor has a structure selected from:
- 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-  
benzamide;
- 30 N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)-  
benzamide;

3,4-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide;

(c) said MEK inhibitor has a structure selected from:

- 2-(2-Chloro-4-iodo-phenylamino)-3,4difluoro-benzoic acid;
- 5 3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
- 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
- 2-(2-Chloro-4-iodo-pyrenylamino)-3,4-difluoro-5-nitro-benzoic acid;
- 10 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-benzoic acid;
- 7-Fluoro-6-(4-iodo-2-methyl-phenylamino)1 *H*-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide;
- 5-Chloro-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;
- and
- 15 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid;
- and

(d) said MEK inhibitor has a structure selected from:

- 2-(2-Chloro-4-iodo-phenylamino)-3,4difluoro-benzoic acid; and
- 7-Fluoro-6-(4-iodo-2-methyl-phenylamino)1 *H*-benzoimidazole-5-
- 20 carboxylic acid cyclopropylmethoxy-amide.

This invention also provides pharmaceutical formulations adapted for the treatment of chronic pain, said formalities comprising a disclosed compound together with a pharmaceutically acceptable excipient, diluent, or carrier. Preferred formulations include any of the foregoing preferred compounds together with an excipient, diluent, or carrier.

The disclosed compounds are potent and selective inhibitors of kinase enzymes, particularly MEK<sub>1</sub> and MEK<sub>2</sub>.



## BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a bar graph representing the paw withdrawal threshold (PWT) in grams as a function of time in days. The empty, cross-hatched, and single-hatched bars are vehicle, PD 198306, and pregabalin, respectively. The arrows indicate time of drug administration (30 mg/kg, p.o.).

FIG 2. is a bar graph representing the force required in grams to elicit paw withdrawal using von Frey hair filaments as a function of time in days. Baseline (BL) measurements were taken before treatment. Animals received a single p.o. administration of PD 198306 (3-30mg/kg), or pregabalin (30mg/kg) and withdrawal thresholds were re-assessed 1h after treatment. Treatments were repeated twice a day for two days. Results are expressed median  $\pm$  1<sup>st</sup> and 3<sup>rd</sup> quartiles. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001 significantly different from vehicle treated animals (Mann-Whitney t test; n=7-8).

FIG. 3. is a bar graph representing the force required in grams to elicit paw withdrawal using von Frey hair filaments as a function of time in days. Baseline (BL) measurements were taken before treatment. Animals received a single p.o. administration of PD 198306 (3-30mg/kg), or pregabalin (30mg/kg) and withdrawal thresholds were re-assessed 1h after treatment. Treatments were repeated twice a day for two days. Results are expressed median  $\pm$  1<sup>st</sup> and 3<sup>rd</sup> quartiles. \*\*P<0.01 significantly different from vehicle treated animals (Mann-Whitney t test; n=6).

FIG. 4. is a bar graph representing the force required in grams to elicit paw withdrawal using von Frey hair filaments as a function of time in days. Baseline (BL) measurements were taken before treatment. Animals received a single i.t. administration of PD 198306 (1-30 $\mu$ g/10 $\mu$ l), or pregabalin (100 $\mu$ g/10 $\mu$ l) and withdrawal thresholds were re-assessed at 30min, 1h and 2h after treatment. Results are expressed median  $\pm$  1<sup>st</sup> and 3<sup>rd</sup> quartiles. \*P<0.05, \*\*\*P<0.001 significantly different from vehicle treated animals (Mann-Whitney t test; n=7-9).

FIG. 5. is a bar graph representing the force required in grams to elicit paw withdrawal using von Frey hair filaments as a function of time in days. Baseline (BL) measurements were taken before treatment. Animals received a single i.t. administration of PD 198306 (1-30 $\mu$ g/10 $\mu$ l), or pregabalin (100 $\mu$ g/10 $\mu$ l) and withdrawal thresholds were re-assessed at 30min, 1h and 2h after treatment. Results are expressed median  $\pm$  1<sup>st</sup> and 3<sup>rd</sup> quartiles. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001 significantly different from vehicle treated animals (Mann-Whitney t test; n=6-8).

FIG. 6 is a bar graph representing the force required in grams to elicit paw withdrawal using von Frey hair filaments as a function of time in days. Animals received a single intraplantar (i.pl.) administration of PD 198306 (3mg/100 $\mu$ l), or an intrathecal injection of PD 198306 (30 $\mu$ g/10 $\mu$ l) and withdrawal thresholds were re-assessed 1h after treatment. Results are expressed median  $\pm$  1<sup>st</sup> and 3<sup>rd</sup> quartiles. \*\*P<0.01 significantly different from vehicle treated animals (Mann-Whitney t test; n=6-9).

FIG. 7. is a bar graph representing the force required in grams to elicit paw withdrawal using von Frey hair filaments as a function of time in days. Animals received a single intraplantar (i.pl.) administration of PD 198306 (3mg/100 $\mu$ l), or an intrathecal injection of PD 198306 (30 $\mu$ g/10 $\mu$ l) and withdrawal thresholds were re-assessed 1h after treatment. Results are expressed median  $\pm$  1<sup>st</sup> and 3<sup>rd</sup> quartiles. \*\*P<0.01 significantly different from vehicle treated animals (Mann-Whitney t test; n=6).

FIG. 8 is a bar graph representing the force required in grams to elicit paw withdrawal using von Frey hair filaments. Baseline (BL) measurements were taken before treatment. Animals received a single i.t. administration of PD219622, PD297447, PD 184352, or PD 254552 (30 $\mu$ g/10 $\mu$ l), or pregabalin (100 $\mu$ g/10 $\mu$ l) and withdrawal thresholds were re-assessed at 30min, 1h and 2h after treatment. Results are expressed median  $\pm$  1<sup>st</sup> and 3<sup>rd</sup> quartiles.



## DETAILED DESCRIPTION

The compounds disclosed herein are pharmaceutically active, for example, they inhibit MEK. MEK enzymes are dual specificity kinases involved in, for example, immunomodulation, inflammation, and proliferative diseases such as cancer and restenosis, as well as pair.

Proliferative diseases are caused by a defect in the intracellular signaling system, or the signal transduction mechanism of certain proteins. Defects include a change either in the intrinsic activity or in the cellular concentration of one or more signaling proteins in the signaling cascade. The cell may produce a growth factor that binds to its own receptors, resulting in an autocrine loop, which continually stimulates proliferation. Mutations or overexpression of intracellular signaling proteins can lead to spurious mitogenic signals within the cell. Some of the most common mutations occur in genes encoding the protein known as Ras, a G-protein that is activated when bound to GTP, and inactivated when bound to GDP. The above-mentioned growth factor receptors, and many other mitogenic receptors, when activated, lead to Ras being converted from the GDP-bound state to the GTP-bound state. This signal is an absolute prerequisite for proliferation in most cell types. Defects in this signaling system, especially in the deactivation of the Ras-GTP complex, are common in cancers, and lead to the signaling cascade below Ras being chronically activated.

Activated Ras leads in turn to the activation of a cascade of serine/threonine kinases. One of the groups of kinases known to require an active Ras-GTP for its own activation is the Raf family. These in turn activate MEK (e.g., MEK<sub>1</sub> and MEK<sub>2</sub>) which then activates MAP kinase, ERK (ERK<sub>1</sub> and ERK<sub>2</sub>). Activation of MAP kinase by mitogens appears to be essential for proliferation; constitutive activation of this kinase is sufficient to induce cellular transformation. Blockade of downstream Ras signaling, for example by use of a dominant negative Raf-1 protein, can completely inhibit mitogenesis, whether induced from cell surface receptors or from oncogenic Ras mutants. Although Ras is not itself a protein kinase, it participates in the activation of Raf and other kinases, most likely through a phosphorylation mechanism.

Once activated, Raf and other kinases phosphorylate MEK on two closely adjacent serine residues, S<sup>218</sup> and S<sup>222</sup> in the case of MEK-1, which are the prerequisite for activation of MEK as a kinase. MEK in turn phosphorylates MAP kinase on both a tyrosine, Y<sup>185</sup>, and a threonine residue, T<sup>183</sup>,  
5 separated by a single amino acid.

This double phosphorylation activates MAP kinase at least 100-fold. Activated MAP kinase can then catalyze the phosphorylation of a large number of proteins, including several transcription factors and other kinases. Many of these MAP kinase phosphorylations are mitogenically activating for  
10 the target protein, such as a kinase, a transcription factor, or another cellular protein. In addition to Raf-1 and MEKK, other kinases activate MEK, and MEK itself appears to be a signal integrating kinase. Current understanding is that MEK is highly specific for the phosphorylation of MAP kinase. In fact, no substrate for MEK other than the MAP kinase, ERK, has been  
15 demonstrated to date and MEK does not phosphorylate peptides based on the MAP kinase phosphorylation sequence, or even phosphorylate denatured MAP kinase. MEK also appears to associate strongly with MAP kinase prior to phosphorylating it, suggesting that phosphorylation of MAP kinase by MEK may require a prior strong interaction between the two proteins. Both this  
20 requirement and the unusual specificity of MEK are suggestive that it may have enough difference in its mechanism of action to other protein kinases that selective inhibitors of MEK, possibly operating through allosteric mechanisms rather than through the usual blockade of the ATP binding site, may be found.

25 The effect of the MEK inhibitor PD 198306 has been investigated in two animal models of neuropathic pain by assessing static allodynia with von Frey hairs.

Oral administration of PD 198306 (3-30mg/kg) had no effect in the model of chronic constriction injury of the sciatic nerve (CCI). However, after repeated  
30 administration (3 doses over two days) it had a transient effect in the diabetic neuropathy model (streptozocin). This may be due to disorders of the blood-brain barrier induced by the diabetic condition in these animals, thus allowing central action of the compound. Intrathecal administration of PD 198306 (1-

WO 01/05392

PCT/US00/18347

30 $\mu$ g) dose-dependently blocked static allodynia in both the streptozocin and the CCI models of neuropathic pain, with minimum effective doses (MED) of 3 and 10 $\mu$ g respectively. The highest dose used (30 $\mu$ g) totally blocked the maintenance of static allodynia, for up to 1h. Intraplantar administration of PD 198306 (3mg/100 $\mu$ l) at a dose 100-fold higher than the dose shown to be effective intrathecally (30 $\mu$ g/10 $\mu$ l) had no effect on static allodynia in either of the neuropathic pain models. This finding confirms the lack of effect seen after systemic administration and suggests a central site of action for the compound.

This study supports the use of MEK inhibitors as potential new therapeutic tools for chronic pain. The study of potential side-effects, especially related to memory, of future brain-penetrant MEK inhibitors will further support the therapeutic window for this novel class of compounds in the treatment of pain.

## A. Terms

Certain terms are defined below and by their usage throughout this disclosure.

Alkyl groups include aliphatic (i.e., hydrocarbyl or hydrocarbon radical structures containing hydrogen and carbon atoms) with a free valence. Alkyl groups are understood to include straight chain and branched structures. Examples include methyl, ethyl, propyl, isopropyl, butyl, n-butyl, isobutyl, t-butyl, pentyl, isopentyl, 2,3-dimethylpropyl, hexyl, 2,3-dimethylhexyl, 1,1-dimethylpentyl, heptyl, and octyl. Cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

Alkyl groups can be substituted with 1, 2, 3 or more substituents which are independently selected from halo (fluoro, chloro, bromo, or iodo), hydroxy, amino, alkoxy, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, arylalkyloxy, heterocyclic radical, and (heterocyclic radical)oxy. Specific examples include fluoromethyl, hydroxyethyl, 2,3-dihydroxyethyl, (2- or 3-furanyl)methyl, cyclopropylmethyl, benzyloxyethyl, (3-pyridinyl)methyl, (2- or 3-furanyl)methyl, (2-thienyl)ethyl, hydroxypropyl, aminocyclohexyl, 2-dimethylaminobutyl, methoxymethyl, N-pyridinylethyl, diethylaminoethyl, and cyclobutylmethyl.

Alkenyl groups are analogous to alkyl groups, but have at least one double bond (two adjacent  $sp^2$  carbon atoms). Depending on the placement of a double bond and substituents, if any, the geometry of the double bond may be *entgegen* (E), or *zusammen* (Z), *cis*, or *trans*. Similarly, alkynyl groups have at least one triple bond (two adjacent  $sp$  carbon atoms).

Unsaturated alkenyl or alkynyl groups may have one or more double or triple bonds, respectively, or a mixture thereof; like alkyl groups, unsaturated groups may be straight chain or branched, and they may be substituted as described both above for alkyl groups and throughout the disclosure by example.

Examples of alkenyls, alkynyls, and substituted forms include *cis*-2-butenyl, *trans*-2-butenyl, 3-butenyl, 3-phenyl-2-propynyl, 3-(2'-fluorophenyl)-2-propynyl, 3-methyl(5-phenyl)-4-pentynyl, 2-hydroxy-2-propynyl, 2-methyl-2-propynyl, 2-propenyl, 4-hydroxy-3-butenyl, 3-(3-fluorophenyl)-2-propynyl, and 2-methyl-2-propenyl. In formula (I), alkenyls and alkynyls can be  $C_{2-4}$  or  $C_{2-8}$ , for example, and are preferably  $C_{3-4}$  or  $C_{3-8}$ .

More general forms of substituted hydrocarbon radicals include hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycycloalkyl, hydroxyaryl, and corresponding forms for the prefixes amino-, halo- (e.g., fluoro-, chloro-, or bromo-), nitro-, alkyl-, phenyl-, cycloalkyl- and so on, or combinations of

5 substituents. According to formula (I), therefore, substituted alkyls include hydroxyalkyl, aminoalkyl, nitroalkyl, haloalkyl, alkylalkyl (branched alkyls, such as methylpentyl), (cycloalkyl)alkyl, phenylalkyl, alkoxy, alkylaminoalkyl, dialkylaminoalkyl, arylalkyl, aryloxyalkyl, arylalkyloxyalkyl, (heterocyclic radical)alkyl, and (heterocyclic radical)oxyalkyl.  $R_1$  thus includes

10 hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycycloalkyl, hydroxyaryl, aminoalkyl, aminoalkenyl, aminoalkynyl, aminocycloalkyl, aminoaryl, alkylalkenyl, (alkylaryl)alkyl, (haloaryl)alkyl, (hydroxyaryl)alkynyl, and so forth. Similarly,  $R_A$  includes hydroxyalkyl and aminoaryl, and  $R_B$  includes hydroxyalkyl, aminoalkyl, and hydroxyalkyl(heterocyclic radical)alkyl.

15 Heterocyclic radicals, which include but are not limited to heteroaryls, include: furyl, oxazolyl, isoxazolyl, thiophenyl, thiazolyl, pyrrolyl, imidazolyl, 1,3,4-triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, indolyl, and their nonaromatic counterparts. Further examples of heterocyclic radicals include piperidyl, quinolyl, isothiazolyl, piperidinyl, morpholinyl, piperazinyl,

20 tetrahydrofuryl, tetrahydropyrrolyl, pyrrolidinyl, octahydroindolyl, octahydrobenzothiofuranyl, and octahydrobenzofuranyl.

Selective MEK 1 or MEK 2 inhibitors are those compounds which inhibit the MEK 1 or MEK 2 enzymes, respectively, without substantially inhibiting other enzymes such as MKK3, PKC, Cdk2A, phosphorylase kinase,

25 EGF, and PDGF receptor kinases, and C-src. In general, a selective MEK 1 or MEK 2 inhibitor has an  $IC_{50}$  for MEK 1 or MEK 2 that is at least one-fiftieth (1/50) that of its  $IC_{50}$  for one of the above-named other enzymes. Preferably, a selective inhibitor has an  $IC_{50}$  that is at least 1/100, more preferably 1/500, and even more preferably 1/1000, 1/5000, or less than that of its  $IC_{50}$  or one or

30 more of the above-named enzymes.



## B. Compounds

As used herein, the term "aryl" means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from five to twelve carbon atoms. Examples of typical aryl groups include phenyl, naphthyl, and fluorenyl. The aryl may be substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, or amino. Typical substituted aryl groups include 3-fluorophenyl, 3,5-dimethoxyphenyl, 4-nitronaphthyl, 2-methyl-4-chloro-7-aminofluorenyl, and the like.

The term "aryloxy" means an aryl group bonded through an oxygen atom, for example phenoxy, 3-bromophenoxy, naphthyloxy, and 4-methyl-1-fluorenyloxy.

"Heteroaryl" means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from four to eleven carbon atoms and one, two, or three heteroatoms selected from O, S, or N. Examples include furyl, thienyl, pyrrolyl, pyrazolyl, triazolyl, thiazolyl, xanthenyl, pyronyl, indolyl, pyrimidyl, naphthyridyl, pyridyl, and triazinyl. The heteroaryl groups can be unsubstituted or substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, or amino. Examples of substituted heteroaryl groups include chloropyranyl, methylthienyl, fluoropyridyl, amino-1,4-benzisoxazinyl, nitroisoquinolinyl, and hydroxyindolyl.

The heteroaryl groups can be bonded through oxygen to make heteroaryloxy groups, for example thienyloxy, isothiazolyloxy, benzofuranyloxy, pyridyloxy, and 4-methylisoquinolinylloxy.

The term "C<sub>1</sub>-C<sub>8</sub> alkyl" means straight and branched chain aliphatic groups having from one to eight carbon atoms. Typical C<sub>1</sub>-C<sub>8</sub> alkyl groups include methyl, ethyl, isopropyl, tert.-butyl, 2,3-dimethylhexyl, and 1,1-dimethylpentyl. The alkyl groups can be unsubstituted or substituted by cycloalkyl, cycloalkyl containing a heteroatom selected from O, S, or NR<sub>9</sub>, aryl, aryloxy, heteroaryl, or heteroaryloxy, as those terms are defined above. Examples of aryl and aryloxy substituted alkyl groups include phenylmethyl, 2-phenylethyl, 3-chlorophenylmethyl, 1,1-dimethyl-3-(2-nitrophenoxy)butyl, and 3,4,5-trifluoronaphthylmethyl. Examples of alkyl groups substituted by a

heteroaryl or heteroaryloxy group include thienylmethyl, 2-furylethyl, 6-furyloxyoctyl, 4-methylquinolyloxymethyl, and 6-isothiazolylhexyl. Cycloalkyl substituted alkyl groups include cyclopropylmethyl, 2-cyclopentylethyl, 2-piperidin-1-ylethyl, 3-(tetrahydropyran-2-yl)propyl, and cyclobutylmethyl.

5       “C<sub>2</sub>-C<sub>8</sub> Alkenyl” means a straight or branched carbon chain having one or more double bonds. Examples include but-2-enyl, 2-methyl-prop-2-enyl, 1,1-dimethyl-hex-4-enyl, 3-ethyl-4-methyl-pent-2-enyl, and 3-isopropyl-pent-4-enyl. The alkenyl groups can be substituted with aryl, aryloxy, heteroaryl, or heteroyloxy, for example 3-phenylprop-2-enyl, 6-thienyl-hex-2-enyl, 2-furyloxy-  
10 but-2-enyl, and 4-naphthyloxy-hex-2-enyl.

      “C<sub>2</sub>-C<sub>8</sub> Alkynyl” means a straight or branched carbon chain having from two to eight carbon atoms and at least one triple bond. Typical alkynyl groups include prop-2-ynyl, 2-methyl-hex-5-ynyl, 3,4-dimethyl-hex-5-ynyl, and 2-ethyl-but-3-ynyl. The alkynyl groups can be substituted by aryl, aryloxy,  
15 heteroaryl, or heteroaryloxy, for example 4-(2-fluorophenyl)-but-3-ynyl, 3-methyl-5-thienylpent-4-ynyl, 3-phenoxy-hex-4-ynyl, and 2-furyloxy-3-methyl-hex-4-ynyl.

      The alkenyl and alkynyl groups can have one or more double bonds or triple bonds, respectively, or a combination of double and triple bonds. For  
20 example, typical groups having both double and triple bonds include hex-2-en-4-ynyl, 3-methyl-5-phenylpent-2-en-4-ynyl, and 3-thienyloxy-hex-3-en-5-ynyl.

      The term “C<sub>3</sub>-C<sub>10</sub> cycloalkyl” means a non-aromatic ring or fused rings containing from three to ten carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, bicycloheptyl, adamantyl, and cyclohexyl.  
25 The ring can optionally contain a heteroatom selected from O, S, or NR<sub>g</sub>. Such groups include tetrahydrofuryl, tetrahydropyrrolyl, octahydrobenzofuranyl, octahydroindolyl, and octahydrobenzothiofuranyl.

      R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> can include groups defined by the term (O or NH)<sub>m</sub>-(CH<sub>2</sub>)<sub>n</sub>-R<sub>g</sub>. Examples of such groups are aminomethyl, 2-aminoethyl,  
30 2-aminoethylamino, 3-aminopropoxy, N,N-diethylamino, 3-(N-methyl-N-isopropylamino)-propylamino, 2-(N-acetylamino)-ethoxy, 4-(N-dimethylaminocarbonylamino)-butoxy, and 3-(N-cyclopropylamino)-propoxy.

As used herein, the term "aryl" means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from five to twelve carbon atoms. Examples of typical aryl groups include phenyl, naphthyl, and fluorenyl. The aryl may be substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, amino, alkylamino, or dialkylamino. Typical substituted aryl groups include 3-fluorophenyl, 3,5-dimethoxyphenyl, 4-nitronaphthyl, 2-methyl-4-chloro-7-aminofluorenyl, and the like.

The term "aryloxy" means an aryl group bonded through an oxygen atom, for example phenoxy, 3-bromophenoxy, naphthyloxy, and 4-methyl-1-fluorenyloxy.

"Heteroaryl" means a cyclic, bicyclic, or tricyclic aromatic ring moiety having from four to eleven carbon atoms and one, two, or three heteroatoms selected from O, S, or N. Examples include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, xanthenyl, pyronyl, indolyl, pyrimidyl, naphthyridyl, pyridyl, benzinnidazolyl, and triazinyl. The heteroaryl groups can be unsubstituted or substituted by one, two, or three groups selected from fluoro, chloro, bromo, iodo, alkyl, hydroxy, alkoxy, nitro, amino, alkylamino, or dialkylamino. Examples of substituted heteroaryl groups include chloropyranyl, methylthienyl, fluoropyridyl, amino-1,4-benzisoxazinyl, nitroisoquinoliny, and hydroxyindolyl.

The heteroaryl groups can be bonded through oxygen to make heteroaryloxy groups, for example thienyloxy, isothiazolyloxy, benzofuranyloxy, pyridyloxy, and 4-methylisoquinolinyloxy.

The term "C<sub>1</sub>-C<sub>8</sub> alkyl" means straight and branched chain aliphatic groups having from one to eight carbon atoms, preferably one to four. Typical C<sub>1</sub>-C<sub>8</sub> alkyl groups include methyl, ethyl, isopropyl, tert.-butyl, 2,3-dimethylhexyl, and 1,1-dimethylpentyl. The alkyl groups can be unsubstituted or substituted by halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, cycloalkyl, aryl, aryloxy, heteroaryl, or heteroaryloxy, as those terms are defined herein. Typical substituted alkyl groups include chloromethyl, 3-hydroxypropyl, 2-dimethylaminobutyl, and 2-(hydroxymethylamino)ethyl. Examples of aryl and aryloxy substituted alkyl groups include phenylmethyl, 2-phenylethyl, 3-chlorophenylmethyl,

1,1-dimethyl-3-(2-nitrophenoxy)butyl, and 3,4,5-trifluoronaphthylmethyl.

Examples of alkyl groups substituted by a heteroaryl or heteroaryloxy group include thienylmethyl, 2-furylethyl, 6-furyloxyoctyl, 4-methylquinolyloxymethyl, and 6-isothiazolyhexyl. Cycloalkyl substituted alkyl groups include

5 cyclopropylmethyl, 2-cyclohexylethyl, piperidyl-2-methyl, 2-(piperidin-1-yl)-ethyl, 3-(morpholin-4-yl)propyl.

“C<sub>2</sub>-C<sub>8</sub> Alkenyl” means a straight or branched carbon chain having one or more double bonds. Examples include but-2-enyl, 2-methyl-prop-2-enyl, 1,1-dimethyl-hex-4-enyl, 3-ethyl-4-methyl-pent-2-enyl, and 3-isopropyl-pent-10 4-enyl. The alkenyl groups can be substituted with halo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, aryl, aryloxy, heteroaryl, or heteroaryloxy, for example 2-bromoethenyl, 3-hydroxy-2-butenyl, 1-aminoethenyl, 3-phenylprop-2-enyl, 6-thienyl-hex-2-enyl, 2-furyloxy-but-2-enyl, and 4-naphthyloxy-hex-2-enyl.

15 “C<sub>2</sub>-C<sub>8</sub> Alkynyl” means a straight or branched carbon chain having from two to eight carbon atoms and at least one triple bond. Typical alkynyl groups include prop-2-ynyl, 2-methyl-hex-5-ynyl, 3,4-dimethyl-hex-5-ynyl, and 2-ethyl-but-3-ynyl. The alkynyl groups can be substituted as the alkyl and alkenyl groups, for example, by aryl, aryloxy, heteroaryl, or heteroaryloxy, for 20 example 4-(2-fluorophenyl)-but-3-ynyl, 3-methyl-5-thienylpent-4-ynyl, 3-phenoxy-hex-4-ynyl, and 2-furyloxy-3-methyl-hex-4-ynyl.

The alkenyl and alkynyl groups can have one or more double bonds or triple bonds, respectively, or a combination of double and triple bonds. For example, typical groups having both double and triple bonds include hex-2-en-25 4-ynyl, 3-methyl-5-phenylpent-2-en-4-ynyl, and 3-thienyloxy-hex-3-en-5-ynyl.

The term “C<sub>3</sub>-C<sub>10</sub> cycloalkyl” means a nonaromatic ring or fused rings containing from three to ten carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, bicycloheptyl, adamantyl, and cyclohexyl. The ring can optionally contain one, two, or three heteroatoms selected from 30 O, S, or NR<sub>g</sub>. Such groups include tetrahydrofuryl, tetrahydropyrrolyl, octahydrobenzofuranyl, morpholinyl, piperazinyl, pyrrolidinyl, piperidinyl, octahydroindolyl, and octahydrobenzothiofuranyl. The cycloalkyl groups can

be substituted with the same substituents as an alkyl and alkenyl groups, for example, halo, hydroxy, aryl, and heteroaryloxy. Examples include 3-hydroxycyclohexyl, 2-aminocyclopropyl, 2-phenylpyrrolidinyl, and 3-thienylmorpholine-1-yl.


- 5           R<sub>6</sub> and R<sub>7</sub> can be taken together with the nitrogen to which they are attached to complete a cyclic ring having from 3 to 10 members, which may contain 1, 2, or 3 additional heteroatoms selected from O, S, NH, or N alkyl. Examples of such cyclic rings include piperazinyl, piperidyl, pyrrolidinyl, morpholino, N-methylpiperazinyl, aziridynyl, and the like. Such rings can be
- 10 substituted with halo, hydroxy, alkyl, alkoxy, amino, alkyl, and dialkylamino, aryl, aryloxy, heteroaryl, and heteroaryloxy. Typical examples include 3-hydroxy-pyrrolidinyl, 2-fluoro-piperindyl, 4-(2-hydroxyethyl)-piperidinyl, and 3-thienylmorpholino.

## C. Synthesis

The 4-bromo and 4-iodo phenylamino benzhydroxamic acid derivatives of Formula I can be prepared from commercially available starting materials utilizing synthetic methodologies well-known to those skilled in organic chemistry. A typical synthesis is carried out by reacting a 4-bromo or 4-iodo aniline with a benzoic acid having a leaving group at the 2-position to give a phenylamino benzoic acid, and then reacting the benzoic acid phenylamino derivative with a hydroxylamine derivative. This process is depicted in Scheme 1.

10

Scheme 1



where L is a leaving group, for example halo such as fluoro, chloro, bromo or iodo, or an activated hydroxy group such as a diethylphosphate, trimethylsilyloxy, p-nitrophenoxy, or phenylsulfonyloxy.


The reaction of the aniline derivative and the benzoic acid derivative  
5 generally is accomplished by mixing the benzoic acid with an equimolar quantity or excess of the aniline in an unreactive organic solvent such as tetrahydrofuran, or toluene, in the presence of a base such as lithium diisopropylamide, n-butyl lithium, sodium hydride, and sodium amide. The reaction generally is carried out at a temperature of about -78°C to about  
10 25°C, and normally is complete within about 2 hours to about 4 days. The product can be isolated by removing the solvent, for example by evaporation under reduced pressure, and further purified, if desired, by standard methods such as chromatography, crystallization, or distillation.

The phenylamino benzoic acid next is reacted with a hydroxylamine  
15 derivative  $\text{HNR}_6\text{OR}_7$  in the presence of a peptide coupling reagent. Hydroxylamine derivatives that can be employed include methoxylamine, N-ethyl-isopropoxy amine, and tetrahydro-oxazine. Typical coupling reagents include 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), 1,3-dicyclohexylcarbodiimide (DCC), bromo-tris(pyrrolidino)-phosphonium  
20 hexafluorophosphate (PyBrOP) and (benzotriazolyloxy)tripyrrolidino phosphonium hexafluorophosphate (PyBOP). The phenylamino benzoic acid and hydroxylamino derivative normally are mixed in approximately equimolar quantities in an unreactive organic solvent such as dichloromethane, tetrahydrofuran, chloroform, or xylene, and an equimolar quantity of the  
25 coupling reagent is added. A base such as triethylamine or diisopropylethylamine can be added to act as an acid scavenger if desired. The coupling reaction generally is complete after about 10 minutes to 2 hours, and the product is readily isolated by removing the reaction solvent, for instance by evaporation under reduced pressure, and purifying the product by  
30 standard methods such as chromatography or crystallizations from solvents such as acetone, diethyl ether, or ethanol.

An alternative method for making the invention compounds involves first converting a benzoic acid to a hydroxamic acid derivative, and then

reacting the hydroxamic acid derivative with an aniline. This synthetic sequence is depicted in Scheme 2.

Scheme 2




- 5 where  $L$  is a leaving group. The general reaction conditions for both of the steps in Scheme 2 are the same as those described above for Scheme 1.

Yet another method for making invention compounds comprises reacting a phenylamino benzhydroxamic acid with an ester forming group as depicted in Scheme 3.



Scheme 3




where L is a leaving group such as halo, and a base is triethylamine or diisopropylamine.

- 5 The synthesis of invention compounds of Formula I is further illustrated by the following detailed examples numbers 1 to 102.

The 2-(4-bromo and 4-iodo phenylamino)-benzoic acid derivatives of Formula I(A) can be prepared from commercially available starting materials utilizing synthetic methodologies well-known to those skilled in organic chemistry and illustrated in synthetic examples 1A - 224A below. A typical synthesis is carried out by reacting a 4-bromo or 4-iodo aniline with a benzoic acid having a leaving group at the 2-position to give a 2-(phenylamino)-benzoic acid. This process is depicted in Scheme 1(A).

Scheme 1(A)



10

where L is a leaving group, for example halo such as fluoro.

The reaction of aniline and the benzoic acid derivative generally is accomplished by mixing the benzoic acid with an equimolar quantity or excess of the aniline in an unreactive organic solvent such as tetrahydrofuran or toluene, in the presence of a base such as lithium diisopropylamide, n-butyl lithium, sodium hydride, triethylamine, and Hunig's base. The reaction generally is carried out at a temperature of about -78°C to about 100°C, and


normally is complete within about 2 hours to about 4 days. The product can be isolated by removing the solvent, for example by evaporation under reduced pressure, and further purified, if desired, by standard methods such as chromatography, crystallization, or distillation.

5           The 2-(phenylamino)-benzoic acid (eg, Formula IA, where R<sub>7</sub> is hydrogen) can be reacted with an organic or inorganic base such as pyridine, triethylamine, calcium carbonate, or sodium hydroxide to produce a pharmaceutically acceptable salt. The free acids can also be reacted with an alcohol of the formula HOR<sub>7</sub> (where R<sub>7</sub> is other than hydrogen, for example  
10 methyl) to produce the corresponding ester. Reaction of the benzoic acid with an alcohol can be carried out in the presence of a coupling agent. Typical coupling reagents include 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), 1,3-dicyclohexylcarbodiimide (DCC), bromo-tris(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP), and (benzotriazolyloxy)  
15 tripyrrolidino phosphonium hexafluorophosphate (PyBOP). The phenylamino benzoic acid and alcohol derivative normally are mixed in approximately equimolar quantities in an unreactive organic solvent such as dichloromethane, tetrahydrofuran, chloroform, or xylene, and an equimolar quantity of the coupling reagent is added. A base such as triethylamine or  
20 diisopropylethylamine can be added to act as an acid scavenger if desired. The coupling reaction generally is complete after about 10 minutes to 2 hours, and the product is readily isolated by removing the reaction solvent, for instance by evaporation under reduced pressure, and purifying the product by standard methods such as chromatography or crystallizations from solvents  
25 such as acetone, diethyl ether, or ethanol.

          The benzamides of the invention, Formula I(A) where Z is CONR<sub>6</sub>R<sub>7</sub>, are readily prepared by reacting the foregoing benzoic acids with an amine of the formula HNR<sub>6</sub>R<sub>7</sub>. The reaction is carried out by reacting approximately  
30 equimolar quantities of the benzoic acid and amine in an unreactive organic solvent in the presence of a coupling reagent. Typical solvents are chloroform, dichloromethane, tetrahydrofuran, benzene, toluene, and xylene. Typical coupling reagents include DCC, EEDQ, PyBrOP, and PyBOP. The reaction is

generally complete after about 10 minutes to about 2 hours when carried out at a temperature of about 0°C to about 60°C. The product amide is readily isolated by removing the reaction solvent, for instance by evaporation, and further purification can be accomplished by normal methods such as chromatography, crystallization, or distillation. The hydrazides (z = CONHNR<sub>10</sub>R<sub>11</sub>) are similarly prepared by coupling a benzoic acid with a hydrazine of the formula H<sub>2</sub>HNR<sub>10</sub>R<sub>11</sub>.

The benzyl alcohols of the invention, compounds of Formula I(A) where Z is CH<sub>2</sub>OR<sub>6</sub> and R<sub>6</sub> is hydrogen, are readily prepared by reduction of the corresponding benzoic acid according to the following scheme



Typical reducing agents commonly employed include borane in tetrahydrofuran. The reduction normally is carried out in an unreactive organic solvent such as tetrahydrofuran, and generally is complete within about 2 hours to about 24 hours when conducted at a temperature of about 0°C to about 40°C.

The following detailed examples 1A to 224A illustrate specific compounds provided by this invention.

#### D. Uses

The disclosed compositions are useful as both prophylactic and therapeutic treatments for diseases or conditions relating to chronic pain, including neuropathic pain, as provided in the Summary section, as well as  
5 diseases or conditions modulated by the MEK cascade. For example, in one embodiment, the disclosed method relates to postoperative pain, phantom limb pain, burn pain, gout, trigeminal neuralgia, acute herpetic and postherpetic pain, causalgia, diabetic neuropathy, plexus avulsion, neuroma, vasculitis, crush injury, constriction injury, tissue injury, post-surgical pain,  
10 arthritis pain, or limb amputation

For example, local injuries can be treated with local or topical administration. Chronic pain affecting the entire body, such as diabetic neuropathy can be treated with systemic administration (injection or orally) of a disclosed composition. Treatment for chronic pain (e.g., post-operative  
15 pain) confined to the lower body can be administered centrally, e.g., epidurally. Formulations and methods of administration can include the use of more than one MEK inhibitor, or a combination of a MEK inhibitor and another pharmaceutical agent, such as an anti-inflammatory, analgesic, muscle relaxing, or anti-infective agent. Preferred routes of administration are oral,  
20 intrathecal or epidural, subcutaneous, intravenous, intramuscular, and, for non-human mammals, intraplantar, and are preferably epidural.

#### 1. Dosages

Those skilled in the art will be able to determine, according to known  
25 methods, the appropriate dosage for a patient, taking into account factors such as age, weight, general health, the type of pain requiring treatment, and the presence of other medications. In general, an effective amount will be between 0.1 and 1000 mg/kg per day, preferably between 1 and 300 mg/kg body weight, and daily dosages will be between 10 and 5000 mg for an adult  
30 subject of normal weight. Commercially available capsules or other

formulations (such as liquids and film-coated tablets) of 100 mg, 200 mg, 300 mg, or 400 mg can be administered according to the disclosed methods.

## 2. Formulations

Dosage unit forms include tablets, capsules, pills, powders, granules, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers adapted for subdivision into individual doses. Dosage unit forms can also be adapted for various methods of administration, including controlled release formulations, such as subcutaneous implants. Administration methods include oral, rectal, parenteral (intravenous, intramuscular, subcutaneous), intracisternal, intravaginal, intraperitoneal, intravesical, local (drops, powders, ointments, gels, or cream), and by inhalation (a buccal or nasal spray).

Parenteral formulations include pharmaceutically acceptable aqueous or nonaqueous solutions, dispersion, suspensions, emulsions, and sterile powders for the preparation thereof. Examples of carriers include water, ethanol, polyols (propylene glycol, polyethylene glycol), vegetable oils, and injectable organic esters such as ethyl oleate. Fluidity can be maintained by the use of a coating such as lecithin, a surfactant, or maintaining appropriate particle size. Carriers for solid dosage forms include (a) fillers or extenders, (b) binders, (c) humectants, (d) disintegrating agents, (e) solution retarders, (f) absorption accelerators, (g) adsorbants, (h) lubricants, (i) buffering agents, and (j) propellants.

Compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents; antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid; isotonic agents such as a sugar or sodium chloride; absorption-prolonging agents such as aluminum monostearate and gelatin; and absorption-enhancing agents.

## 3. Related compounds

The invention provides the disclosed compounds and closely related, pharmaceutically acceptable forms of the disclosed compounds, such as salts, esters, amides, hydrates or solvated forms thereof; masked or protected forms; and racemic mixtures, or enantiomerically or optically pure forms.

Pharmaceutically acceptable salts, esters, and amides include carboxylate salts (e.g., C<sub>1-8</sub> alkyl, cycloalkyl, aryl, heteroaryl, or non-aromatic heterocyclic), amino acid addition salts, esters, and amides which are within a reasonable benefit/risk ratio, pharmacologically effective, and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate. These may include alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine. See, for example, S.M. Berge, et al., "Pharmaceutical Salts," *J. Pharm. Sci.*, 1977, 66:1-19 which is incorporated herein by reference. Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary C<sub>1-6</sub> alkyl amines and secondary di (C<sub>1-6</sub> alkyl) amines. Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms. Preferred amides are derived from ammonia, C<sub>1-3</sub> alkyl primary amines, and di (C<sub>1-2</sub> alkyl)amines. Representative pharmaceutically acceptable esters of the invention include C<sub>1-7</sub> alkyl, C<sub>5-7</sub> cycloalkyl, phenyl, and phenyl(C<sub>1-6</sub>)alkyl esters. Preferred esters include methyl esters.

The invention also includes disclosed compounds having one or more functional groups (e.g., hydroxyl, amino, or carboxyl) masked by a protecting group. Some of these masked or protected compounds are pharmaceutically acceptable; others will be useful as intermediates. Synthetic intermediates and processes disclosed herein, and minor modifications thereof, are also within the scope of the invention.

## HYDROXYL PROTECTING GROUPS

Hydroxyl protecting groups include: ethers, esters, and protection for 1,2- and 1,3-diols. The ether protecting groups include: methyl, substituted methyl ethers, substituted ethyl ethers, substituted benzyl ethers, silyl ethers and  
 5 conversion of silyl ethers to other functional groups.

### Substituted Methyl Ethers

Substituted methyl ethers include: methoxymethyl, methylthiomethyl, *t*-  
 utylthiomethyl, (phenyldimethylsilyl) methoxymethyl, benzyloxymethyl, *p*-  
 ethoxybenzyloxymethyl, (4-methoxyphenoxy) methyl, guaiacolmethyl, *t*-  
 10 butoxymethyl, 4-pentenylloxymethyl, siloxymethyl, 2-methoxyethoxymethyl,  
 2,2,2-trichloroethoxymethyl, bis(2-chloro- ethoxy)methyl, 2-  
 (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydro-pyranyl,  
 tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-  
 methoxytetrahydrothio-pyranyl, 4-methoxytetrahydrothiopyranyl *S,S*-dioxido,  
 15 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1,4-dioxan-2-yl,  
 tetrahydrofuran-2-yl, tetrahydrothiofuran-2-yl, and 2,3,3a,4,5,6,7,7a-octahydro-  
 7,8,8-trimethyl-4,7-ethanobenzofuran-2-yl.

### Substituted Ethyl Ethers

Substituted ethyl ethers include: 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl,  
 20 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-  
 fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilyl-ethyl, 2-(phenylselenyl)ethyl, *t*-  
 butyl, allyl, *p*-chlorophenyl, *p*-methoxyphenyl, 2,4-dinitrophenyl, and benzyl.

### Substituted Benzyl Ethers

Substituted benzyl ethers include: *p*-methoxybenzyl, 3,4-dimethoxybenzyl,  
 25 *o*-nitrobenzyl, *p*-nitrobenzyl, *p*-halobenzyl, 2,6-dichlorobenzyl, *p*-cyanobenzyl,  
*p*-phenylbenzyl, 2- and 4-picolyl, 3-methyl-2-picolyl *N*-oxido, diphenylmethyl,  
*p*, *p*'-dinitrobenzhydryl, 5-dibenzosuberone, triphenylmethyl,  $\alpha$ -naphthylidiphenyl-  
 methyl, *p*-methoxyphenyldiphenylmethyl, di(*p*-methoxyphenyl)phenylmethyl,  
 tri(*p*-methoxyphenyl)methyl, 4-(4'-bromophenacyloxy)phenyldiphenylmethyl,  
 30 4,4',4''-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4''-  
 tris(levulinoyloxyphenyl) methyl, 4,4',4''tris(benzoyloxyphenyl)methyl, 3-  
 (imidazol-1-ylmethyl)bis(4',4''-dimethoxyphenyl)-methyl, 1,1-bis(4-  
 methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl) xanthenyl, 9-(9-



phenyl-10-oxo) anthryl, 1,3-benzodithiolan-2-yl, and benzisothiazolyl S,S-dioxido.

#### Silyl Ethers

Silyl ethers include: trimethylsilyl, triethylsilyl, triisopropylsilyl, 5 dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, tri-*p*-xylylsilyl, triphenylsilyl, diphenylmethylsilyl, and *t*-butylmethoxyphenylsilyl.

#### ESTERS

10 Esters protecting groups include: esters, carbonates, assisted cleavage, miscellaneous esters, and sulfonates.

#### Esters

Examples of protective esters include: formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, 15 methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, *p*-chlorophenoxyacetate, *p*-P-phenylacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio) pentanoate, pivaloate, adamantate, crotonate, 4-methoxycrotonate, benzoate, *p*-phenylbenzoate, and 2,4,6-trimethylbenzoate (mesitoate).

#### 20 Carbonates

Carbonates include: methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl) ethyl, 2-(phenylsulfonyl) ethyl, 2-(triphenylphosphonio) ethyl, isobutyl, vinyl, allyl, *p*-nitrophenyl, benzyl, *p*-methoxybenzyl, 3,4- 25 dimethoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl, and methyl dithiocarbonate.

#### Assisted Cleavage

Examples of assisted cleavage protecting groups include: 2-iodobenzoate, 4- azido-butyrates, 4-nitro-4-methylpentanoate, *o*-(dibromomethyl) benzoate, 2- formylbenzene-sulfonate, 2-(methylthiomethoxy) ethyl carbonate, 4- 30 (methylthiomethoxymethyl) benzoate, and 2-(methylthiomethoxymethyl) benzoate.

Miscellaneous Esters

- In addition to the above classes, miscellaneous esters include: 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl) phenoxyacetate, 2,4-bis(1,1-dimethylpropyl) phenoxyacetate, 5 chlorodiphenylacetate, isobutyrate, monosuccinoate, (*E*)-2-methyl-2-butenate (tigloate), *o*-(methoxycarbonyl) benzoate, *p*-P-benzoate,  $\alpha$ -naphthoate, nitrate, alkyl *N,N,N',N'*-tetramethylphosphorodiamidate, *N*-phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4-dinitrophenylsulfenate.

10 Sulfonates

Protective sulfates includes: sulfate, methanesulfonate(mesylate), benzylsulfonate, and tosylate.

PROTECTION FOR 1,2- AND 1,3-DIOLS

- 15 The protection for 1,2 and 1,3-diols group includes: cyclic acetals and ketals, cyclic ortho esters, and silyl derivatives.

Cyclic Acetals and Ketals

- Cyclic acetals and ketals include: methylene, ethylidene, 1-*t*-butylethylidene, 1-phenylethylidene, (4-methoxyphenyl) ethylidene, 2,2,2-trichloroethylidene, 20 acetonide (isopropylidene), cyclopentylidene, cyclohexylidene, cycloheptylidene, benzylidene, *p*-methoxybenzylidene, 2,4-dimethoxybenzylidene, 3,4-dimethoxybenzylidene, and 2-nitrobenzylidene.

Cyclic Ortho Esters

- Cyclic ortho esters include: methoxymethylene, ethoxymethylene, dimethoxy- 25 methylene, 1-methoxyethylidene, 1-ethoxyethylidene, 1,2-dimethoxyethylidene,  $\alpha$ -methoxybenzylidene, 1-(*N,N*-dimethylamino)ethylidene derivative,  $\alpha$ -(*N,N*-dimethylamino) benzylidene derivative, and 2-oxacyclopentylidene.

30

PROTECTION FOR THE CARBOXYL GROUPESTERS

Ester protecting groups include: esters, substituted methyl esters, 2-substituted ethyl esters, substituted benzyl esters, silyl esters, activated  
 5 esters, miscellaneous derivatives, and stannyl esters.

Substituted Methyl Esters

Substituted methyl esters include: 9-fluorenylmethyl, methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxy-methyl, benzyloxymethyl, phenacyl, *p*-bromophenacyl,  
 10  $\alpha$ -methylphenacyl, *p*-methoxyphenacyl, carboxamidomethyl, and *N*-phthalimidomethyl.

2-Substituted Ethyl Esters

2-Substituted ethyl esters include: 2,2,2-trichloroethyl, 2-haloethyl,  $\alpha$ -chloroalkyl, 2-(trimethylsilyl)ethyl, 2-methylthioethyl, 1,3-dithianyl-2-methyl,  
 15 2(*p*-nitrophenylsulfenyl)-ethyl, 2-(*p*-toluenesulfonyl)ethyl, 2-(2'-pyridyl)ethyl, 2-(diphenylphosphino)ethyl, 1-methyl-1-phenylethyl, *t*-butyl, cyclopentyl, cyclohexyl, allyl, 3-buten-1-yl, 4-(trimethylsilyl)-2-buten-1-yl, cinnamyl,  $\alpha$ -methylcinnamyl, phenyl, *p*-(methylmercapto)-phenyl, and benzyl.

Substituted Benzyl Esters

Substituted benzyl esters include: triphenylmethyl, diphenylmethyl, bis(*o*-nitrophenyl)methyl, 9-anthrylmethyl, 2-(9,10-dioxo)anthrylmethyl, 5-dibenzo-suberyl, 1-pyrenylmethyl, 2-(trifluoromethyl)-6-chromylmethyl, 2,4,6-trimethylbenzyl, *p*-bromobenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, *p*-methoxybenzyl, 2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4-sulfobenzyl,  
 25 piperonyl, and 4-P-benzyl.

Silyl Esters

Silyl esters include: trimethylsilyl, triethylsilyl, *t*-butyldimethylsilyl, *i*-propyldimethylsilyl, phenyldimethylsilyl, and di- *t*-butylmethylsilyl.

Miscellaneous Derivatives

Miscellaneous derivatives includes: oxazoles, 2-alkyl-1,3-oxazolines, 4-alkyl-5-oxo-1,3-oxazolidines, 5-alkyl-4-oxo-1,3-dioxolanes, ortho esters, phenyl group, and pentaaminocobalt(III) complex.

Stannyl Esters

Examples of stannyl esters include: triethylstannyl and tri-*n*-butylstannyl.

## AMIDES AND HYDRAZIDES

- 5 Amides include: *N,N*-dimethyl, pyrrolidinyl, piperidinyl, 5,6-dihydrophenanthridinyl, *o*-nitroanilides, *N*-7-nitroindolyl, *N*-8-nitro-1,2,3,4-tetrahydroquinolyl, and *p*-P-benzenesulfonamides. Hydrazides include: *N*-phenyl, *N,N'*-diisopropyl and other dialkyl hydrazides.

10 PROTECTION FOR THE AMINO GROUPCARBAMATES

Carbamates include: carbamates, substituted ethyl, assisted cleavage, photolytic cleavage, urea-type derivatives, and miscellaneous carbamates.

15 Carbamates

Carbamates include: methyl and ethyl, 9-fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7-di-*t*-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydro-thioxanthyl)]methyl, and 4-methoxyphenacyl.

Substituted Ethyl

- 20 Substituted ethyl protective groups include: 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-1-(4-biphenyl)ethyl, 1-(3,5-di-*t*-butylphenyl)-1-methylethyl, 2-(2'-and 4'-pyridyl)ethyl, 2-(*N,N*-isyclohexylcarboxamido)- ethyl, *t*-butyl, 1-adamantyl,
- 25 vinyl, allyl, 1-isopropylallyl, connamyl, 4-nitrocinnamyl, quinolyl, *N*-hydroxypiperidinyl, alkylidithio, benzyl, *p*-methoxybenzyl, *p*-nitrobenzyl, *p*-bromobenzyl, *p*-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl, 9-anthrylmethyl, and diphenylmethyl.

30 Assisted Cleavage

Protection via assisted cleavage includes: 2-methylthioethyl, 2-methylsulfonylethyl, 2-(*p*-toluenesulfonyl)ethyl, [2-(1,3-dithianyl)]methyl, 4-methylthiophenyl, 2,4-dimethyl-thiophenyl, 2-phosphonioethyl,

2-triphenylphosphonioisopropyl, 1,1-dimethyl-2cyanoethyl, *m*-chloro-*p*-acyloxybenzyl, *p*-(dihydroxyboryl)benzyl, 5-benzisoxazolyl-methyl, and 2-(trifluoromethyl)-6-chromonylmethyl.

#### Photolytic Cleavage

- 5 Photolytic cleavage methods use groups such as: *m*-nitrophenyl, 3,5-dimethoxybenzyl, *o*-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, and phenyl(*o*-nitrophenyl)methyl.

#### Urea-Type Derivatives

- Examples of of urea-type derivatives include: phenothiazinyl-(10)-carbonyl derivative, *N*'-*p*-toluenesulfonylaminocarbonyl, and *N*'-phenylaminothiocarbonyl.

#### Miscellaneous Carbamates

- In addition to the above, miscellaneous carbamates include: *t*-amyl, *S*-benzyl thiocarbamate, *p*-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, 15 cyclopropylmethyl, *p*-decyloxy-benzyl, diisopropylmethyl, 2,2-dimethoxycarbonylvinyl, *o*-(*N,N*-dimethyl-carboxamido)-benzyl, 1,1-dimethyl-3(*N,N*-dimethylcarboxamido)propyl, 1,1-dimethyl-propynyl, di(2-pyridyl)methyl, 2-furanylmethyl, 2-iodoethyl, isobornyl, isobutyl, isonicotinyl, *p*(*p*'-methoxyphenyl- azo)benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1- 20 methyl-1-cyclopropyl- methyl, 1-methyl-(3,5-dimethoxyphenyl)ethyl, 1-methyl-1(*p*-henylazophenyl)- ethyl, 1-methyl-1-phenylethyl, 1-methyl-1-(4-pyridyl)ethyl, phenyl, *p*-(phenylazo)benzyl, 2,4,6-tri-*t*-butylphenyl, 4-(trimethylammonium) benzyl, and 2,4,6-trimethylbenzyl.

### 25 AMIDES

#### Amides

- Amides includes: *N*-formyl, *N*-acetyl, *N*-chloroacetyl, *N*-trichloroacetyl, *N*-trifluoroacetyl, *N*-phenylacetyl, *N*-3-phenylpropionyl, *N*-picolinoyl, *N*-3-pyridyl-carboxamide, *N*-benzoylphenylalanyl derivative, *N*-benzoyl, and *N*-*p*- 30 phenylbenzoyl.

#### Assisted Cleavage

Assisted cleavage groups include: *N*-*o*-nitrophenylacetyl, *N*-*o*-nitrophenoxycetyl, *N*-acetoacetyl, (*N*'-dithiobenzyloxycarbonylamino)acetyl,

- N*-3-(*p*-hydroxyphenyl) propionyl, *N*-3-(*o*-nitrophenyl)propionyl, *N*-2-methyl-2-(*o*-nitrophenoxy)propionyl, *N*-2-methyl-2-(*o*-phenylazophenoxy)propionyl, *N*-4-chlorobutyryl, *N*-3-methyl-3-nitrobutyryl, *N*-*o*-nitrocinnamoyl, *N*-acetylmethionine derivative, *N*-*o*-nitrobenzoyl, *N*-*o*-(benzoyloxymethyl)benzoyl, and 4,5-diphenyl-3-oxazolin-2-one.

#### Cyclic Imide Derivatives

- Cyclic imide derivatives include: *N*-phthalimide, *N*-dithiasuccinoyl, *N*-2,3-diphenyl-maleoyl, *N*-2,5-dimethylpyrrolyl, *N*-1,1,4,4-tetramethyldisilylazacyclopentane adduct, 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, and 1-substituted 3,5-dinitro-4-pyridonyl.

#### SPECIAL -NH PROTECTIVE GROUPS

- Protective groups for –NH include: *N*-alkyl and *N*-aryl amines, imine derivatives, enamine derivatives, and *N*-hetero atom derivatives (such as *N*-metal, *N*-N, *N*-P, *N*-Si, and *N*-S), *N*-sulfenyl, and *N*-sulfonyl.

#### *N*-Alkyl and *N*-Aryl Amines

- N*-alkyl and *N*-aryl amines include: *N*-methyl, *N*-allyl, *N*-[2-(trimethylsilyl)ethoxyl]-methyl, *N*-3-acetoxypentyl, *N*-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl), quaternary ammonium salts, *N*-benzyl, *N*-di(4-methoxyphenyl)methyl, *N*-5-dibenzosuberyl, *N*-triphenylmethyl, *N*-(4-methoxyphenyl)diphenylmethyl, *N*-9-phenylfluorenyl, *N*-2,7-dichloro-9-fluorenylmethylene, *N*-ferrocenylmethyl, and *N*-2-picolylamine *N*'-oxide.

#### Imine Derivatives

- Imine derivatives include: *N*-1,1-dimethylthiomethylene, *N*-benzylidene, *N*-*p*-methoxybenzylidene, *N*-diphenylmethylene, *N*-[(2-pyridyl)mesityl]methylene, *N*-(*N*',*N*'-dimethylaminomethylene), *N*,*N*'-isopropylidene, *N*-*p*-nitrobenzylidene, *N*-salicylidene, *N*-5-chlorosalicylidene, *N*-(5-chloro-2-hydroxyphenyl)phenyl-methylene, and *N*-cyclohexylidene.

Enamine Derivative

An example of an enamine derivative is *N*-(5,5-dimethyl-3-oxo-1-cyclohexenyl).

N-Hetero Atom Derivatives

- 5 *N*-metal derivatives include: *N*-borane derivatives, *N*-diphenylborinic acid derivative, *N*-[phenyl(pentacarbonylchromium- or -tungsten)]carbenyl, and *N*-copper or *N*-zinc chelate. Examples of *N-N* derivatives include: *N*-nitro, *N*-nitroso, and *N*-oxide. Examples of *N-P* derivatives include: *N*-diphenylphosphinyl, *N*-dimethylthiophosphinyl, *N*-diphenylthiophosphinyl,
- 10 *N*-dialkyl phosphoryl, *N*-dibenzyl phosphoryl, and *N*-diphenyl phosphoryl. Examples of *N*-sulfenyl derivatives include: *N*-benzenesulfenyl, *N*-*o*-nitrobenzenesulfenyl, *N*-2,4-dinitrobenzenesulfenyl, *N*-pentachlorobenzenesulfenyl, *N*-2-nitro-4-methoxy-benzenesulfenyl, *N*-triphenylmethylsulfenyl, and *N*-3-nitropyridinesulfenyl. *N*-sulfonyl
- 15 derivatives include: *N*-*p*-toluenesulfonyl, *N*-benzenesulfonyl, *N*-2,3,6-trimethyl-4-methoxybenzenesulfonyl, *N*-2,4,6-trimethoxybenzenesulfonyl, *N*-2,6-dimethyl-4-methoxybenzenesulfonyl, *N*-pentamethylbenzenesulfonyl, *N*-2,3,5,6-tetramethyl-4-methoxybenzene-sulfonyl,
- 20 *N*-4-methoxybenzenesulfonyl, *N*-2,4,6-trimethylbenzenesulfonyl, *N*-2,6-dimethoxy-4-methylbenzenesulfonyl, *N*-2,2,5,7,8-pentamethylchroman-6-sulfonyl, *N*-methanesulfonyl, *N*- $\beta$ -trimethylsilylethanesulfonyl, *N*-9-anthracenesulfonyl, *N*-4-(4',8'-dimethoxynaphthylmethyl)-benzenesulfonyl, *N*-benzylsulfonyl,
- 25 *N*-trifluoromethylsulfonyl, and *N*-phenacylsulfonyl.

- Disclosed compounds which are masked or protected may be prodrugs, compounds metabolized or otherwise transformed *in vivo* to yield a disclosed compound, e.g., transiently during metabolism. This transformation may be a
- 30 hydrolysis or oxidation which results from contact with a bodily fluid such as blood, or the action of acids, or liver, gastrointestinal, or other enzymes.

Features of the invention are further described in the examples below.

## E. Examples

## BIOLOGICAL EXAMPLES

5

## EXAMPLE 1

**Effect of PD 198306 on streptozocin-induced static allodynia**Animals

Male Sprague Dawley rats (250-300g), obtained from Bantin and Kingman, (Hull, U.K.) were housed in groups of 3. All animals were kept under a 12h light/dark cycle (lights on at 07h 00min) with food and water *ad libitum*. All experiments were carried out by an observer blind to drug treatments.

Development of diabetes in the rat

Diabetes was induced in rats by a single i.p. injection of streptozocin (50 mg/kg) as described previously (Courteix et al., 1993).

Evaluation of static allodynia

Mechanical hypersensitivity was measured using Semmes-Weinstein von Frey hairs (Stoelting, Illinois, U.S.A.). Animals were placed into wire mesh bottom cages allowing access to the underside of their paws. Animals were habituated to this environment prior to the start of the experiment. Mechanical hypersensitivity was tested by touching the plantar surface of the animals right hind paw with von Frey hairs in ascending order of force ( 0.7, 1.2, 1.5, 2, 3.6, 5.5, 8.5, 11.8, 15.1 and 29g) for up to 6 sec. Once a withdrawal response was established, the paw was re-tested, starting with the next descending von Frey hair until no response occurred. The highest force of 29 g lifted the paw as well as eliciting a response, thus represented the cut off point. The lowest amount of force required to elicit a response was recorded as the paw withdrawal threshold (PWT) in grams.

30



### Drugs

PD 198306 [N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide] and CI-1008 (pregabalin) were synthesized at Parke-Davis (Ann Arbor, MI, USA). PD 198306 was suspended in cremophor:ethanol:water (1:1:8) vehicle. Pregabalin was dissolved in water. Both compounds were administered orally. Streptozocin (Aldrich, UK) was dissolved in 0.9% w/v NaCl and administered intraperitoneally. Drug administrations were made in a volume of 1 ml/kg.

### 10 Statistics

The static allodynia data were analysed using a Kruskal-Wallis ANOVA for non-parametric results, followed when significant by Mann-Whitney's t test.

### Experimental protocol

15 Static allodynia was assessed with von Frey hairs, before (baseline, BL) and 1h after oral administration of PD 198306 (30mg/kg, p.o.), vehicle (cremophor:ethanol:water, 1:1:8) or pregabalin (30mg/kg, p.o.) (test). Animals were administered again the same compounds on the following day, both in the morning and the afternoon. Static allodynia was assessed only  
20 before and 1h after the afternoon administration, in order to minimise the habituation of the animals to the testing conditions. Animals treated with pregabalin received water in the morning administration, in order to avoid the potential development of tolerance to the compound with repeated  
25 administration.

#### Day 1:

p.m.: BL

PD 198306

#### Day 2:

a.m.: PD 198306

Water

Vehicle

p.m.: BL

PD 198306

Pregabalin  
Vehicle  
Test

Pregabalin  
Vehicle  
Test

## 5 RESULTS

A single administration of pregabalin (30mg/kg, p.o.) significantly blocked streptozocin-induced static allodynia 1h after administration. In contrast, a single administration of PD 198306 (30mg/kg, p.o) had no effect on streptozocin-induced static allodynia 1h after administration (see below).  
10 However, after the compound had been administered twice more on the following day, it significantly blocked streptozocin-induced static allodynia 1h after the third administration. The effects had disappeared by the following day (see FIG. 1).

## 15 EXAMPLE 2

### MATERIALS AND METHODS

#### Animals

Male Sprague Dawley rats (250-300g), obtained from Charles River, Margate, U.K.) were housed in groups of 3-6. All animals were kept under a  
20 12h light/dark cycle (lights on at 07h 00min) with food and water *ad libitum*. All experiments were carried out by an observer blind to drug treatments.

Diabetes was induced in rats by a single i.p. injection of streptozocin (50mg/kg) as described previously (Courteix et al., 1993).

#### 25 Development of Chronic Constriction Injury in the rat

Animals were anaesthetised with 2% isoflurane 1:4 O<sub>2</sub>/N<sub>2</sub>O mixture maintained during surgery via a nose cone. The sciatic nerve was ligated as previously described by Bennett and Xie, 1988. Animals were placed on a homeothermic blanket for the duration of the procedure. After surgical  
30 preparation the common sciatic nerve was exposed at the middle of the thigh by blunt dissection through biceps femoris. Proximal to the sciatic trifurcation, about 7mm of nerve was freed of adhering tissue and 4 ligatures (4-0 silk)

were tied loosely around it with about 1mm spacing. The incision was closed in layers and the wound treated with topical antibiotics.

#### Intrathecal injections

5 PD 198306 and pregabalin were administered intrathecally in a volume of 10  $\mu$ l using a 100  $\mu$ l Hamilton syringe by exposing the spine of the rats under brief isoflurane anaesthesia. Injections were made into the intrathecal space between lumbar region 5-6 with a 10 mm long 27 gauge needle. Penetrations were judged successful if there was a tail flick response. The wound was sealed  
10 with an autoclip and rats appeared fully awake within 2-3 min following injection.

#### Evaluation of static allodynia

Mechanical hypersensitivity was measured using Semmes-Weinstein von Frey hairs (Stoelting, Illinois, U.S.A.). Animals were placed into wire mesh  
15 bottom cages allowing access to the underside of their paws. Animals were habituated to this environment prior to the start of the experiment. Mechanical hypersensitivity was tested by touching the plantar surface of the animals right hind paw with von Frey hairs in ascending order of force ( 0.7, 1.2, 1.5, 2, 3.6, 5.5, 8.5, 11.8, 15.1 and 29g) for up to 6sec. Once a withdrawal response was  
20 established, the paw was re-tested, starting with the next descending von Frey hair until no response occurred. The highest force of 29g lifted the paw as well as eliciting a response, thus represented the cut off point. The lowest amount of force required to elicit a response was recorded as the paw withdrawal threshold (PWT) in grams.

25

#### Experimental protocol

Static allodynia was assessed with von Frey hairs, before (baseline, BL) and 0.5h, 1h and 2h after intrathecal or intraplantar administration of PD 198306 (1-30 $\mu$ g, i.t.), vehicle (cremophor:ethanol:water, 1:1:8) or pregabalin  
30 (10 $\mu$ g, i.t). For oral administration experiments, static allodynia was assessed with von Frey hairs, before (baseline, BL) and 1h after oral administration of PD 198306 (3-30mg/kg, p.o.), vehicle (cremophor:ethanol:water, 1:1:8) or pregabalin (30mg/kg, p.o.). Animals were administered again the same

compounds on the following day, both in the morning and the afternoon. Static allodynia was assessed before and 1h after the morning administration. In the afternoon static allodynia was assessed before, 1h, 2h and 3h after administration for streptozocin treated animals. CCI animals were assessed before, 1h and 2h after administration

#### Drugs used

PD 198306 and pregabalin were synthesised at Parke-Davis (Ann Arbor, MI, USA). PD 198306 was suspended in cremophor:ethanol:water (1:1:8) vehicle. Pregabalin was dissolved in water. Both compounds were administered orally, intrathecally or intraplantar in volumes of 1ml/kg, 10µl and 100µl respectively. Streptozocin (Aldrich, UK) was dissolved in 0.9% w/v NaCl and administered intraperitoneally in a volume of 1ml/kg.

#### Statistics

Data were analysed using a Kruskal-Wallis ANOVA for non-parametric results, followed when significant by Mann-Whitney's t test vs vehicle group.

### RESULTS

#### **1. Effects of PD 198306 on static allodynia, following systemic administration**

##### 1.1. Effect of PD198306 on streptozocin-induced static allodynia

A single administration of pregabalin (30mg/kg, p.o.) significantly blocked streptozocin-induced static allodynia 1h after administration. In contrast, a single administration of PD 198306 (3-30mg/kg, p.o) had no effect on streptozocin-induced static allodynia 1h after administration (FIG. 2). However, after the compound had been administered twice more on the following day, PD 198306 (30mg/kg) significantly blocked streptozocin-induced static allodynia for 2h after the third administration (FIG. 2).

##### 1.2. Effect of PD198306 on CCI-induced static allodynia

A single administration of pregabalin (30mg/kg, p.o.) significantly blocked CCI-induced static allodynia 1h after administration. In contrast, neither a single or

multiple administration of PD 198306 (3-30mg/kg, p.o) had any effect on CCI-induced static allodynia (FIG. 3).

## 2. Effects of PD 198306 on static allodynia, following intrathecal administration

Intrathecally administered PD198306 (1-30 $\mu$ g) dose-dependently blocked the maintenance of static allodynia in both streptozocin (FIG. 4) and CCI animals (FIG. 5) with respective MEDs of 3 and 10  $\mu$ g. This antiallodynic effect lasted for 1h.

## 3. Effects of PD 198306 on static allodynia, following intraplantar administration

An intrathecal administration of PD 198306 (30 $\mu$ g) significantly blocked static allodynia in both neuropathic pain models (FIGS. 6,7). In contrast, a single administration of PD 198306 at a dose 100-fold higher (3mg/100 $\mu$ l) directly into the paw had no effect on streptozocin (FIG. 6) or CCI-induced static allodynia (FIG. 7).

## REFERENCES

Bennett GJ, Xie Y-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87-107.

Courteix C, Eschalier A and Lavarenne J. Streptozocin –induced rats: behavioural evidence for a model of chronic pain. Pain 1993;53:81-8

## EXAMPLE 3

### Effect of other MEK inhibitors in a neuropathic pain model in the rat

## SUMMARY

The effect of several MEK inhibitors, with different binding affinities, has been investigated in the CCI model of neuropathic pain in the rat, by assessing static allodynia with von Frey hairs. Intrathecal administration of PD219622 or PD297447 (30 $\mu$ g) had no significant effect on allodynia. This lack of effect

may reflect the low affinity or solubility of the compounds. However, intrathecal administration of PD 254552 or PD 184352 (30µg), which possesses higher binding affinities, blocked the maintenance of static allodynia in CCI animals. The antiallodynic effect was only evident for 30min post-injection and thus, shorter than the one observed for pregabalin (100µg). The magnitude of the effect was similar for 30µg of PD 184352 and 100µg of pregabalin. From this study it is concluded that MEK inhibitors exert an antiallodynic effect in CCI-induced neuropathic rats when administered intrathecally, and that the antiallodynic effect correlates with the affinity of the compounds.

The animals and methods for developing chronic constriction injury in the rat, injecting test compounds, and evaluation of static allodynia were according to Example 2 above. PD219622, PD297447, PD 184352, PD 254552 and pregabalin were administered intrathecally at doses of 30 µg for all PD compounds and 100µg for pregabalin. Static allodynia was assessed with von Frey hairs, before (baseline, BL) and 0.5h, 1h and 2h after intrathecal administration of the compounds

#### Drugs used

PD297447, PD219622, PD 254552, PD 184352 (CI-1040), and pregabalin were synthesised at Parke-Davis (Ann Arbor, MI, USA). PD297447, PD219622, PD 254552 and PD 184352 were suspended in cremophor:ethanol:water (1:1:8) vehicle. Pregabalin was dissolved in water. All compounds were administered intrathecally in a 10µl volume.

#### Statistics

Data were analysed using a Kruskal-Wallis ANOVA for non-parametric results, followed when significant by Mann-Whitney's t test vs vehicle group.

#### RESULTS

Intrathecally administered PD297447 or PD219622 (30µg) had no significant effect on allodynia. This lack of effect may reflect the low affinity of the compounds (965nM and 100nM respectively). However, intrathecal

WO 01/05392

PCT/US00/18347

administration of PD 184352 or PD 254552 (30 $\mu$ g) blocked the maintenance of static allodynia in CCI animals (see FIG. 8). These compounds possess higher affinity (2 and 5 nM respectively). The antiallodynic effect was only evident for 30min post-injection and thus, shorter than the one observed for pregabalin (100 $\mu$ g). The magnitude of the effect was similar for 30 $\mu$ g of PD 184352 and 100 $\mu$ g of pregabalin.

The results indicate that MEK inhibitors exert an antiallodynic effect in CCI-induced neuropathic rats when administered intrathecally, and that the antiallodynic effect correlates with the affinity of the compounds.

10

## CHEMICAL EXAMPLES

## EXAMPLE 1

**4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide**5 (a) **Preparation of 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid**

To a stirred solution containing 3.16 g (0.0133 mol) of 2-amino-5-iodotoluene in 5 mL of tetrahydrofuran at -78°C was added 10 mL (0.020 mol) of a 2.0 M lithium diisopropylamide in 10 tetrahydrofuran/heptane/ethylbenzene (Aldrich) solution. The resulting green suspension was stirred vigorously for 15 minutes, after which time a solution of 1.00 g (0.00632 mol) of 2,4-difluorobenzoic acid in 10 mL of tetrahydrofuran was added. The reaction temperature was allowed to increase slowly to room temperature, at which temperature the mixture was stirred for 2 days. The 15 reaction mixture was concentrated by evaporation of the solvent under reduced pressure. Aqueous HCl (10%) was added to the concentrate, and the solution was extracted with dichloromethane. The organic phase was dried (MgSO<sub>4</sub>) and then concentrated over a steambath to low volume (10 mL) and cooled to room temperature. The off-white fibers which formed were collected 20 by vacuum filtration, rinsed with hexane, and dried in a vacuum-oven (76°C; ca. 10 mm of Hg) to afford 1.10 g (47%) of the desired material; mp 224-229.5°C;

<sup>1</sup>H NMR (400 MHz, DMSO): δ 9.72 (s, 1H), 7.97 (dd, 1H, J=7.0, 8.7 Hz), 7.70 (d, 1H, J=1.5 Hz), 7.57 (dd, 1H, J=8.4, 1.9 Hz), 7.17 (d, 1H, J=8.2 Hz), 25 6.61-6.53 (m, 2H), 2.18 (s, 3H);

<sup>13</sup>C NMR (100 MHz, DMSO): δ 169.87, 166.36 (d, J<sub>C-F</sub>=249.4 Hz), 150.11 (d, J<sub>C-F</sub>=11.4 Hz), 139.83, 138.49, 136.07, 135.26 (d, J<sub>C-F</sub>=11.5 Hz), 135.07, 125.60, 109.32, 104.98 (d, J<sub>C-F</sub>=21.1 Hz), 99.54 (d, J<sub>C-F</sub>=26.0 Hz), 89.43, 17.52;

30 <sup>19</sup>F NMR (376 MHz, DMSO): δ -104.00 to -104.07 (m);

IR (KBr) 1670 (C=O stretch)cm<sup>-1</sup>;

MS (CI) M+1 = 372.



Analysis calculated for  $C_{14}H_{11}FINO_2$ :

C, 45.31; H, 2.99; N, 3.77.

Found: C, 45.21; H, 2.77; N, 3.64.

(b) **Preparation of 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide**

To a stirred solution of 4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid (0.6495 g, 0.001750 mol), O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.2590 g, 0.002211 mol), and diisopropylethylamine (0.40 mL, 0.0023 mol) in 31 mL of an equivolume tetrahydrofuran-dichloromethane solution was added 1.18 g (0.00227 mol) of solid PyBOP ([benzotriazolyloxy]tripyrrolidino phosphonium hexafluorophosphate, Advanced ChemTech) directly. The reaction mixture was stirred for 30 minutes after which time it was concentrated in vacuo. The brown oil was treated with 10% aqueous hydrochloric acid. The suspension was extracted with ether. The organic extraction was washed with 10% sodium hydroxide followed by another 10% hydrochloric acid wash, was dried ( $MgSO_4$ ) and concentrated in vacuo to afford 1.0 g of a light-brown foam. This intermediate was dissolved in 25 mL of ethanolic hydrogen chloride, and the solution was allowed to stand at room temperature for 15 minutes. The reaction mixture was concentrated in vacuo to a brown oil that was purified by flash silica chromatography. Elution with dichloromethane  $\rightarrow$  dichloromethane-methanol (166:1) afforded 0.2284 g of a light-brown viscous oil. Scratching with pentane-hexanes and drying under high vacuum afforded 0.1541 g (23%) of an off-white foam; mp 61-75°C;

$^1H$  NMR (400 MHz, DMSO):  $\delta$  11.34 (s, 1H), 9.68 (s, 1H), 9.18 (s, 1H), 7.65 (d, 1H,  $J=1.5$  Hz), 7.58 (dd, 1H,  $J=8.7, 6.8$  Hz), 7.52 (dd, 1H,  $J=8.4, 1.9$  Hz), 7.15 (d, 1H,  $J=8.4$  Hz), 6.74 (dd, 1H,  $J=11.8, 2.4$  Hz), 6.62 (ddd, 1H,  $J=8.4, 8.4, 2.7$  Hz), 2.18 (s, 3H);

$^{13}C$  NMR (100 MHz, DMSO):  $\delta$  165.91, 164.36 (d,  $J_{C-F}=247.1$  Hz), 146.78, 139.18, 138.77, 135.43, 132.64, 130.60 (d,  $J_{C-F}=11.5$  Hz), 122.23, 112.52, 104.72 (d,  $J=22.1$  Hz), 100.45 (d,  $J_{C-F}=25.2$  Hz), 86.77, 17.03;

$^{19}\text{F}$  NMR (376 MHz, DMSO):  $\delta$  -107.20 to -107.27 (m);

IR (KBr) 3307 (broad, O-H stretch), 1636 (C=O stretch)  $\text{cm}^{-1}$ ;

MS (CI)  $M+1 = 387$ .

Analysis calculated for  $\text{C}_{14}\text{H}_{12}\text{FIN}_2\text{O}_2$ :

5 C, 43.54; H, 3.13; N, 7.25.

Found: C, 43.62; H, 3.24; N, 6.98.

## EXAMPLE 2

### **5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide**

#### 10 (a) **Preparation of 5-Bromo-2,3,4-trifluorobenzoic acid**

To a stirred solution comprised of 1-bromo-2,3,4-trifluorobenzene (Aldrich, 99%; 5.30 g, 0.0249 mol) in 95 mL of anhydrous tetrahydrofuran cooled to  $-78^\circ\text{C}$  was slowly added 12.5 mL of 2.0 M lithium diisopropylamide in heptane/tetrahydrofuran/ethylbenzene solution (Aldrich). The mixture was stirred for 1 hour and transferred by canula into 700 mL of a stirred saturated ethereal carbon dioxide solution cooled to  $-78^\circ\text{C}$ . The cold bath was removed, and the reaction mixture was stirred for 18 hours at ambient temperature. Dilute (10%) aqueous hydrochloric acid (ca. 500 mL) was poured into the reaction mixture, and the mixture was subsequently concentrated on a rotary

20 evaporator to a crude solid. The solid product was partitioned between diethyl ether (150 mL) and aq. HCl (330 mL, pH 0). The aqueous phase was extracted with a second portion (100 mL) of diethyl ether, and the combined ethereal extracts were washed with 5% aqueous sodium hydroxide (200 mL) and water (100 mL, pH 12). These combined alkaline aqueous extractions

25 were acidified to pH 0 with concentrated aqueous hydrochloric acid. The resulting suspension was extracted with ether ( $2 \times 200$  mL). The combined organic extracts were dried ( $\text{MgSO}_4$ ), concentrated in vacuo, and subjected to high vacuum until constant mass was achieved to afford 5.60 g (88% yield) of an off-white powder; mp  $139\text{--}142.5^\circ\text{C}$ ;

30  $^1\text{H}$  NMR (400 MHz, DMSO):  $\delta$  13.97 (broad s, 1H, 8.00-7.96 (m, 1H);

$^{13}\text{C}$  NMR (100 MHz, DMSO):  $\delta$  162.96, 129.34, 118.47, 104.54 (d,  $J_{\text{C-F}}=22.9$  Hz);

$^{19}\text{F}$  NMR (376 MHz, DMSO):  $\delta$  -120.20 to -120.31 (m), -131.75 to -131.86 (m), -154.95 to -155.07 (m);

5 IR (KBr) 1696 (C=O stretch) $\text{cm}^{-1}$ ;

MS (CI)  $M+1 = 255$ .

Analysis calculated for  $\text{C}_7\text{H}_2\text{BrF}_3\text{O}_2$ :

C, 32.97; H, 0.79; N, 0.00; Br, 31.34; F, 22.35.

Found: C, 33.18; H, 0.64; N, 0.01; Br, 30.14; F, 22.75.

10 (b) **Preparation of 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid**

To a stirred solution comprised of 1.88 g (0.00791 mol) of 2-amino-5-iodotoluene in 10 mL of tetrahydrofuran at  $-78^\circ\text{C}$  was added 6 mL (0.012 mol) of a 2.0 M lithium diisopropylamide in

15 tetrahydrofuran/heptane/ethylbenzene (Aldrich) solution. The resulting green suspension was stirred vigorously for 10 minutes, after which time a solution of 1.00 g (0.00392 mol) of 5-bromo-2,3,4-trifluorobenzoic acid in 15 mL of tetrahydrofuran was added. The cold bath was subsequently removed, and the reaction mixture stirred for 18 hours. The mixture was concentrated, and  
20 the concentrate was treated with 100 mL of dilute (10%) aqueous hydrochloric acid. The resulting suspension was extracted with ether ( $2 \times 150$  mL), and the combined organic extractions were dried ( $\text{MgSO}_4$ ) and concentrated in vacuo to give an orange solid. The solid was triturated with boiling dichloromethane, cooled to ambient temperature, and collected by filtration. The solid was  
25 rinsed with dichloromethane, and dried in the vacuum-oven ( $80^\circ\text{C}$ ) to afford 1.39 g (76%) of a yellow-green powder; mp  $259.5\text{--}262^\circ\text{C}$ ;

$^1\text{H}$  NMR (400 MHz, DMSO):  $\delta$  9.03 (s, 1H), 7.99 (dd, 1H,  $J=7.5, 1.9$  Hz), 7.57 (dd, 1H,  $J=1.5$  Hz), 7.42 (dd, 1H,  $J=8.4, 1.9$  Hz), 6.70 (dd, 1H,  $J=8.4, 6.0$  Hz), 2.24 (s, 3H);

30  $^{19}\text{F}$  NMR (376 MHz, DMSO):  $\delta$  -123.40 to -123.47 (m); -139.00 to -139.14 (m);

IR (KBr) 1667 (C=O stretch) $\text{cm}^{-1}$ ;

MS (CI)  $M+1 = 469$ .

Analysis calculated for  $\text{C}_{14}\text{H}_9\text{BrF}_2\text{INO}_2$ :

C, 35.93; H, 1.94; N, 2.99; Br, 17.07; F, 8.12; I, 27.11.

5 Found: C, 36.15; H, 1.91; N, 2.70; Br, 16.40; F, 8.46; I, 26.05.

**(c) Preparation of 5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide**

To a stirred solution comprised of 5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid (0.51 g, 0.0011 mol), O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.15 g, 0.0013 mol), and diisopropylethylamine (0.25 mL, 0.0014 mol) in 20 mL of an equivolume tetrahydrofuran-dichloromethane solution was added 0.6794 g (0.001306 mol) of solid PyBOP (Advanced ChemTech) directly. The reaction mixture was stirred at 24°C for 10 minutes, and then was concentrated to dryness in vacuo. The concentrate was suspended in 100 mL of 10% aqueous hydrochloric acid. The suspension was extracted with 125 mL of diethyl ether. The ether layer was separated, washed with 75 mL of 10% aqueous sodium hydroxide, and then with 100 mL of dilute acid. The ether solution was dried ( $\text{MgSO}_4$ ) and concentrated in vacuo to afford 0.62 g (100%) of an off-white foam. The foam was dissolved in ca. 15 mL of methanolic hydrogen chloride. After 5 minutes, the solution was concentrated in vacuo to an oil, and the oil was purified by flash silica chromatography. Elution with dichloromethane  $\rightarrow$  dichloromethane-methanol (99:1) afforded 0.2233 g (42%) of a yellow powder. The powder was dissolved in diethyl ether and washed with dilute hydrochloric acid. The organic phase was dried ( $\text{MgSO}_4$ ) and concentrated in vacuo to afford 0.200 g of a foam. This product was triturated with pentane to afford 0.1525 g of a powder that was repurified by flash silica chromatography. Elution with dichloromethane afforded 0.0783 g (15%) of an analytically pure title compound, mp 80-90°C;  $^1\text{H}$  NMR (400 MHz, DMSO):  $\delta$  11.53 (s, 1H), 9.38 (s, 1H), 8.82 (s, 1H), 7.70 (dd, 1H,  $J=7.0, 1.9$  Hz), 7.53 (s, 1H), 7.37 (dd, 1H,  $J=8.4, 1.9$  Hz), 6.55 (dd, 1H,  $J=8.2, 6.5$  Hz), 2.22 (s, 3H);

$^{19}\text{F}$  NMR (376 MHz, DMSO):  $\delta$  -126.24 to -126.29 (m), -137.71 to -137.77 (m);

IR (KBr) 3346 (broad, O-H stretch), 1651 (C=O stretch) $\text{cm}^{-1}$ ;

MS (CI)  $M+1 = 484$ .

5 Analysis calculated for  $\text{C}_{14}\text{H}_{10}\text{BrF}_2\text{IN}_2\text{O}_2$ :

C, 34.81; H, 2.09; N, 5.80.

Found: C, 34.53; H, 1.73; N, 5.52,

Examples 3 to 12 and 78 to 102 in the table below were prepared by the general procedures of Examples 1 and 2.

## 10 EXAMPLES 13-77

Examples 13 to 77 were prepared utilizing combinatorial synthetic methodology by reacting appropriately substituted phenylamino benzoic acids

15 (e.g., as shown in Scheme 1) and hydroxylamines (e.g.,  $\text{HN-O-R}_6$ ). A general method is given below:

To a 0.8 mL autosampler vial in a metal block was added 40  $\mu\text{L}$  of a 0.5 M solution of the acid in DMF and 40  $\mu\text{L}$  of the hydroxylamine (2 M solution in Hunig's base and 1 M in amine in DMF). A 0.5 M solution of  
20 PyBrop was freshly prepared, and 50  $\mu\text{L}$  were added to the autosampler vial. The reaction was allowed to stand for 24 hours.

The reaction mixture was transferred to a 2 dram vial and diluted with 2 mL of ethyl acetate. The organic layer was washed with 3 mL of distilled water and the water layer washed again with 2 mL of ethyl acetate. The  
25 combined organic layers were allowed to evaporate to dryness in an open fume hood.

The residue was taken up in 2 mL of 50% acetonitrile in water and injected on a semi-prep reversed phase column (10 mm  $\times$  25 cm, 5  $\mu\text{M}$  spherical silica, pore Size 115 A derivatised with C-18, the sample was eluted  
30 at 4.7 mL/min with a linear ramp to 100% acetonitrile over 8.5 minutes. Elution with 100% acetonitrile continued for 8 minutes.) Fractions were collected by monitoring at 214 nM. The desired fractions were evaporated using a Zymark

Turbovap. The product was dissolved in chloroform and transferred to a preweighed vial, evaporated, and weighed again to determine the yield. The structure was confirmed by mass spectroscopy.

## EXAMPLES 3-102

Example No.	Compound	Melting Point (°C)	MS (M-H <sup>+</sup> )
3	2-(4-bromo-2-methyl-phenylamino)-4-fluoro-N-hydroxy-benzamide	56-75 dec	523
4	5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide	65 dec	
5	5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide	62-67	
6	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(terahydropyran-2-yloxy)benzamide	105-108	
7	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methoxybenzamide	64-68	
8	4-Fluoro-N-hydroxy-2-(4-fluoro-2-methyl-phenylamino)-benzamide	119-135	
9	4-Fluoro-N-hydroxy-2-(2-methyl-phenylamino)-benzamide	101-103	
10	4-Fluoro-2-(4-fluor-2-methyl-phenylamino)-N-(terahydropyran-2-yloxy)benzamide	142-146	

WO 01/05392

PCT/US00/18347

Example No.	Compound	Melting Point (°C)	MS (M-H+)
11	4-Fluoro-N-hydroxy-2-(4-fluoro-2-methyl-phenylamino)-benzamide	133.5-135	
12	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide	107-109.5	
13	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide		399
14	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide		417
15	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-methoxy-benzamide		369
16	2-(4-Bromo-2-methyl-phenylamino)-N-ethoxy-3,4-difluoro-benzamide		342* (M-EtO)
17	5-Bromo-N-ethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		509
18	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		445
19	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-isopropoxy-benzamide		397
20	4-Fluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide		465

Example No.	Compound	Melting Point (°C)	MS (M-H+)
21	3,4-Difluoro-N-(furan-3-ylmethoxy)- 2-(4-iodo-2-methyl-phenylamino)-benzamide		483
22	2-(4-Bromo-2-methyl-phenylamino)- 3,4-difluoro-N-(furan-3-ylmethoxy)- benzamide		435
23	5-Bromo-3,4-difluoro-N-(furan-3-ylmethoxy)- 2-(4-iodo-2-methyl-phenylamino)-benzamide		561
24	5-Bromo-N-(but-2-enyloxy)-3,4-difluoro- 2-(4-iodo-2-methyl-phenylamino)-benzamide		536
25	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)- N-(prop-2-ynyloxy)-benzamide		423
26	3,4-Difluoro-2-(4-iodo-2-methyl- phenylamino)-N-(prop-2-ynyloxy)- benzamide		441
27	3,4-Difluoro-2-(4-iodo-2-methyl- phenylamino)-N-(1-methyl-prop-2-ynyloxy)- benzamide		455
28	2-(4-Bromo-2-methyl-phenylamino)- 3,4-difluoro-N-(1-methyl-prop-2-ynyloxy)- benzamide		407
29	N-(But-3-ynyloxy)-3,4-difluoro-2-(4-iodo- 2-methyl-phenylamino)-benzamide		455



Example No.	Compound	Melting Point (°C)	MS (M-H <sup>+</sup> )
30	2-(4-Bromo-2-methyl-phenylamino)-N-(but-3-ynyloxy)-3,4-difluoro-benzamide		407
31	5-Bromo-N-(but-3-ynyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		533
32	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-phenyl-prop-2-ynyloxy)-benzamide		517
33	3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-phenyl-prop-2-ynyloxy)-benzamide		469
34	3,4-Difluoro-N-[3-(3-fluoro-phenyl)-prop-2-ynyloxy]-2-(4-iodo-2-methyl-phenylamino)-benzamide		535
35	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-[3-(3-fluoro-phenyl)-prop-2-ynyloxy]-benzamide		487
36	3,4-Difluoro-N-[3-(2-fluoro-phenyl)-prop-2-ynyloxy]-2-(4-iodo-2-methyl-phenylamino)-benzamide		535
37	5-Bromo-3,4-difluoro-N-[3-(2-fluoro-phenyl)-prop-2-ynyloxy]-2-(4-iodo-2-methyl-phenylamino)-benzamide		613

WO 01/05392

PCT/US00/18347

Example No.	Compound	Melting Point (°C)	MS (M-H+)
39	2-(4-Bromo-2-methyl-phenylamino)- 3,4-difluoro-N-(3-methyl-5-phenyl-pent-2-en- 4-ynyloxy)-benzamide		510
40	N-Ethoxy-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzamide		431
41	2-(4-Bromo-2-methyl-phenylamino)-N- ethoxy-3,4-difluoro-benzamide		383
42	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)- N-propoxy-benzamide		427
43	3,4-Difluoro-2-(4-iodo-2-methyl- phenylamino)-N-propoxy-benzamide		445
44	2-(4-Bromo-2-methyl-phenylamino)- 3,4-difluoro-N-propoxy-benzamide		397
45	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-N-propoxy-benzamide		523
46	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)- N-isopropoxy-benzamide		427
47	3,4-Difluoro-2-(4-iodo-2-methyl- phenylamino)-N-isopropoxy-benzamide		445
48	2-(4-Bromo-2-methyl-phenylamino)- 3,4-difluoro-N-isopropoxy-benzamide		397

WO 01/05392

PCT/US00/18347

Example No.	Compound	Melting Point (°C)	MS (M-H+)
49	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide		523
50	N-Cyclobutyloxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
51	2-(4-Bromo-2-methyl-phenylamino)-N-cyclobutyloxy-3,4-difluoro-benzamide		409
52	N-Cyclopentyloxy-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		453
53	N-Cyclopentyloxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		471
54	2-(4-Bromo-2-methyl-phenylamino)-N-cyclopentyloxy-3,4-difluoro-benzamide		423
55	N-Cyclopropylmethoxy-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		439
56	N-Cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
57	2-(4-Bromo-2-methyl-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide		409
58	5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)		435

Example No.	Compound	Melting Point (°C)	MS (M-H+)
59	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxy-ethoxy)-benzamide		505
60	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxy-ethoxy)-benzamide		523
61	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-phenoxy-ethoxy)-benzamide		475
62	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(thiophen-2-ylmethoxy)-benzamide		481
63	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(thiophen-2-ylmethoxy)-benzamide		499
64	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(thiophen-2-ylmethoxy)-benzamide		451
65	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-allyloxy)-benzamide		439
66	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-allyloxy)-benzamide		457

Example No.	Compound	Melting Point (°C)	MS (M-H+)
67	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-methyl-allyloxy)-benzamide		410
68	N-(But-2-enyloxy)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		439
69	N-(But-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
70	2-(4-Bromo-2-methyl-phenylamino)-N-(but-2-enyloxy)-3,4-difluoro-benzamide		410
71	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide		441
72	N-(But-3-ynyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		455
73	2-(4-Bromo-2-methyl-phenylamino)-N-(4,4-dimethyl-pent-2-ynyloxy)-3,4-difluoro-benzamide		449
74	N-(But-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide		457
75	2-(4-Bromo-2-methyl-phenylamino)-N-(but-2-enyloxy)-3,4-difluoro-benzamide		410

WO 01/05392

PCT/US00/18347

Example No.	Compound	Melting Point (°C)	MS (M-H+)
76	N-(3-tert.-butyl-propyn-2-yl)oxy-4-fluoro- 2-(4-iodo-2-methyl-phenylamino)-benzamide		479
77	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)- N-phenylmethoxy-benzamide		577* *Cl
78	4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl- phenylamino)-N-isopropyl-benzamide	oil	
79	N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4- iodo-2-methyl-phenylamino)-benzamide	125-127	
80	4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl- phenylamino)-N-methyl-benzamide	45-55	
81	4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl- phenylamino)-5-nitro-benzamide	208-209 (GLASS)	
82	2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy- 4-nitro-benzamide	199-200	
83	3,4-Difluoro-2-(4-iodo-2-methyl- phenylamino)-N-(tetrahydro-pyran-2-yloxy)- benzamide	163-165	
84	3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl- phenylamino)-benzamide	65-75	

Example No.	Compound	Melting Point (°C)	MS (M-H+)
85	3,4-Difluoro-5-bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethoxy)-benzamide	95	
86	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide	167-169	
87	2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide (HCl salt)	165-169	
88	2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide	166-167.5	
89	3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-benzamide	173-174	
90	3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide	121-122	
91	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)-3,4-difluoro-benzamide monohydrochloride salt	206-211.5 DEC	
92	5-Bromo-N-(2-dimethylamino-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	95-105	

Example No.	Compound	Melting Point (°C)	MS (M-H+)
93	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide	266-280 DEC	
94	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide	167.5-169.5	
95	3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-benzamide	172.5-173.5	
96	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide	171-172.5	
97	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethoxy)-benzamide	173.5-175	
98	5-Bromo-N-(2-diethylamino-ethoxy)-3,4-difluoro-(4-iodo-2-methyl-phenylamino)-benzamide	81 DEC	
99	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isobutoxy-benzamide	126-128	
100	5-Bromo-N-cyclohexylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	139-142	



Example No.	Compound	Melting Point (°C)	MS (M-H+)
101	5-Bromo-N-cyclopentylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	113-115	
102	5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	138-139	

The invention compounds are useful in treating chronic pain proliferative diseases by virtue of their selective inhibition of the dual specificity protein kinases MEK<sub>1</sub> and MEK<sub>2</sub>. The invention compound has been evaluated in a number of biological assays which are normally utilized to establish inhibition of proteins and kinases, and to measure mitogenic and metabolic responses to such inhibition.

#### EXAMPLE 1A

##### 4-Fluoro-2-(4-iodo-2-methylphenylamino)benzoic acid

To a stirring solution comprised of 3.16 g (0.0133 mol) of 2-amino-5-iodotoluene in 5 mL of tetrahydrofuran at -78°C was added 10 mL (0.020 mol) of a 2.0 M lithium diisopropylamide in tetrahydrofuran/heptane/ethenylbenzene (Aldrich) solution. The resulting green suspension was stirred vigorously for 15 minutes, after which time a solution of 1.00 g (0.00632 mol) of 2,4-difluorobenzoic acid in 10 mL of tetrahydrofuran was added. The reaction temperature was allowed to increase slowly to room temperature, at which temperature it was stirred for 2 days. The reaction mixture was concentrated. Aqueous HCl (10%) was added to the concentrate, and the solution was extracted with dichloromethane. The organic phase was dried (MgSO<sub>4</sub>) and then boiled over a steambath to low volume and cooled to room temperature. The off-white fibers were collected by vacuum filtration, rinsed with hexanes, and vacuum-oven dried. (76°C; ca. 10 mm of Hg) to afford 1.10 g (47%) of the desired material; mp 224-229.5°C;

WO 01/05392

PCT/US00/18347

$^1\text{H}$  NMR (400 MHz; DMSO):  $\delta$  9.72 (s, 1H), 7.97 (dd, 1H,  $J$  = 7.0, 8.7 Hz), 7.70 (d, 1H,  $J$  = 1.5 Hz), 7.57 (dd, 1H,  $J$  = 8.4, 1.9 Hz), 7.17 (d, 1H,  $J$  = 8.2 Hz), 6.61-6.53 (m, 2H), 2.18 (s, 3H);

$^{13}\text{C}$  NMR (100 MHz; DMSO):  $\delta$  169.87, 167.60, 165.12, 150.17, 150.05,  
5 139.83, 138.49, 136.07, 135.31, 135.20, 135.07, 125.60, 109.32, 105.09, 104.87, 99.72, 99.46, 89.43, 17.52;

$^{19}\text{F}$  NMR (376 MHz; DMSO):  $\delta$  -104.00 to -104.07 (m);

IR (KBr) 1670 (C = O stretch)  $\text{cm}^{-1}$ ;

MS (CI)  $M+1$  = 372.

10 Analysis calculated for  $\text{C}_{14}\text{H}_{11}\text{FINO}_2$ :

C, 45.31; H, 2.99; N, 3.77.

Found: C, 45.21; H, 2.77; N, 3.64.

#### EXAMPLES 2A-30A

By following the general procedure of Example 1A, the following  
15 benzoic acids and salts were prepared:

Example No.	Compound	MP $^{\circ}\text{C}$
2A	3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	206-210
3A	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	240.5-244.5
4A	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	259.5-262
5A	5-Chloro-2-(2-chloro-4-iodo-phenylamino)-benzoic acid	255-260
6A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	234-238

Example No.	Compound	MP °C
7A	Sodium 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoate	310-320 DE C
8A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	239.5-240
9A	2-(2-Chloro-4-iodo-phenylamino)-5-nitro-benzoic acid	289-293
10A	4-Fluoro-2-(3-fluoro-4-iodo-2-methyl-phenylamino)-benzoic acid	233-235
11A	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-benzoic acid	264-267
12A	2-(2-Fluoro-4-iodo-phenylamino)-5-nitro-benzoic acid	256-258
13A	2-(4-Bromo-2-methyl-phenylamino)-4-fluoro-benzoic acid	218.5-220
14A	2-(2-Bromo-4-iodo-phenylamino)-5-nitro-benzoic acid	285-288 DE C
15A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-benzoic acid	230-234
16A	3-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	218-221
17A	3,4-Difluoro-2-(4-iodo-2-methoxy-phenylamino)-benzoic acid	230-233

Example No.	Compound	MP °C
18A	4-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	245-255 DE C
19A	2-(4-Iodo-2-methyl-phenylamino)-benzoic acid	218-223
20A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	243-46
21A	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	241-245
26A	2-Fluoro-6-(4-iodo-2-methyl-phenylamino)-benzoic acid	179-182
27A	4-Fluoro-2-(2,3-dimethyl-4-iodo-2-methyl-phenylamino)-benzoic acid	258-261
28A	5-Methyl-2-(4-iodo-2-methyl-phenylamino)-benzoic acid	209.5-211
29A	2-Chloro-6-(4-iodo-2-methyl-phenylamino)-benzoic acid	171-175
30A	2-(4-Iodo-2-methyl-phenylamino)-4-nitro-benzoic acid	251-263

## EXAMPLE 31A

5-Chloro-N-(2-hydroxyethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide

To a stirring solution comprised of 0.1020 g (0.2632 mmol) of 5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid, 0.1 mL (1.7 mmol) of  
 5 ethanolamine, and 0.05 mL (0.29 mmol) of diisopropylethylamine in 5 mL of a

WO 01/05392

PCT/US00/18347

- 1:1 (v/v) tetrahydrofuran-dichloromethane solution was added 0.15 g  
(0.29 mmol) of solid PyBOP powder directly. The reaction mixture was stirred  
at room temperature overnight. The solvent was removed in vacuo. The crude  
residue was partitioned between ether (50 mL) and 10% aqueous hydrochloric  
5 acid (50 mL). The organic phase was washed with 10% aqueous sodium  
hydroxide (50 mL), dried ( $\text{MgSO}_4$ ) and concentrated in vacuo to afford a  
yellow-brown oil which was crystallized from hexanes-ether to afford 0.0831 g  
(73%) of a green-yellow powder; mp 120-121°C;  
 $^1\text{H}$  NMR (400 MHz;  $\text{CDCl}_3$ ):  $\delta$  9.11 (s, 1H); 7.56 (d, 1H,  $J = 1.4$  Hz),  
10 7.46-7.41 (m, 2H), 7.20 (dd, 1H,  $J = 8.9, 2.4$  Hz), 7.00 (t, 2H,  $J = 9.6$  Hz),  
6.55 (broad t, 1H), 3.86 (t, 2H,  $J = 5.0$  Hz), 3.61 (dd, 2H,  $J = 10.1, 5.5$  Hz),  
2.23 (s, 3H), 1.56 (broad s, 1H);  
IR (KBr) 3297 (O-H stretch), 1627 (C = O stretch)  $\text{cm}^{-1}$ ;  
MS (CI)  $M+1 = 431$ .  
15 Analysis calculated for  $\text{C}_{16}\text{H}_{16}\text{ClIN}_2\text{O}_2$ :  
C, 44.62; H, 3.74; N, 6.50.  
Found: C, 44.63; H, 3.67; N, 6.30.

## EXAMPLES 32-48A

- By following the general procedure of Example 31A, the following  
20 benzamides were prepared by reacting the corresponding benzoic acid with  
the corresponding amine.

Example No.	Compound	MP °C
32A	4-Methoxy-N-(4-methoxy-phenyl)-3-nitro-benzamide	153.5-156
33A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	158
34A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide	102.5-104.5
35A	N-Ethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	90-91
36A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide	oil
37A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1H-tetrazol-5-yl)-benzamide	285-288 DE C
38A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	180-182
39A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide	137-138
40A	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoylamino]-acetic acid	170-173
41A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-propyl-benzamide	69-71
42A	5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	132-133.4
43A	N,N-Diethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	oil
44A	4-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide	122-124
45A	N,N-Diethyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	91-93
46A	N-Butyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	97-99

Example No.	Compound	MP °C
47A	5-Chloro-N,N-diethyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	118-120
48A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide	142.5-144

## EXAMPLE 49A

A4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzyl alcohol4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid (0.50 g, 1.35 mmol) was dissolved in 6 mL (6 mmol) of cold 1.0 M borane-tetrahydrofuran complex in tetrahydrofuran solution. The reaction mixture was stirred under nitrogen atmosphere at room temperature overnight. The reaction was quenched with 80 mL of methanol. Concentration in vacuo produced a clear tan oil which was purified by MPLC. Elution with dichloromethane afforded 0.4285 g (89%) of a white solid; mp 99-100.5°C;

<sup>1</sup>H NMR (400 MHz; DMSO): δ 7.57 (d, 1H, J=1.7 Hz), 7.45 (dd, 1H, J=8.4, 1.9 Hz), 7.39 (s, 1H), 7.29 (t, 1H, J=7.5 Hz), 6.89 (d, 1H, J=8.4 Hz), 6.67-6.60 (m, 1H), 5.47 (t, 1H, J=5.5 Hz), 4.49 (d, 2H, 5.1 Hz), 2.14 (s, 3H); IR (KBr) 3372 (O-H stretch) cm<sup>-1</sup>; MS (CI) M+1 = 358.

Analysis calculated for C<sub>14</sub>H<sub>13</sub>FINO:

C, 47.08; H, 3.67; N, 3.92.

Found: C, 47.17; H, 3.75; N, 3.72.

## EXAMPLE 50A-52A

The following benzyl alcohols were prepared by the general procedure of Example 49A.

Example No.	Compound	MP °C
50A	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol	82-85
51A	[2-(4-Iodo-2-methyl-phenylamino)-5-nitro-phenyl]-methanol	126.5-128.5
52A	[5-Bromo-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol	60.5-63.5

Several invention compounds of Formula I(A) were prepared utilizing combinatorial synthetic techniques. The general procedure is as follows:

To a 0.8-mL autosampler vial in a metal block was added 40  $\mu$ L of a 0.5 M solution of the acid in DMF and 40  $\mu$ L of the reagent amine (2M solution in Hunig's base and 1 M in amine in DMF). A 0.5M solution of PyBrop was freshly prepared and 50  $\mu$ L were added to the autosampler vial. The reaction was allowed to stand for 24 hours.

The reaction mixture was transferred to a 2-dram vial and diluted with 2 mL of ethyl acetate. The organic layer was washed with 3 mL of distilled water and the water layer washed again with 2 mL of ethyl acetate. The combined organic layers were allowed to evaporate to dryness in an open fume hood.

The residue was taken up in 2 mL of 50% acetonitrile in water and injected on a semi-prep reversed phase column (10 mm  $\times$  25 cm, 5  $\mu$ M spherical silica, pore size 115 A derivatized with C-18, the sample was eluted at 4.7 mL/min with a linear ramp to 100% acetonitrile over 8.5 minutes. Elution with 100% acetonitrile continued for 8 minutes). Fractions were collected by monitoring at 214 nM. The residue was dissolved in chloroform and transferred to a preweighed vial, evaporated, and weighed again to determine the yield.



## EXAMPLES 53A-206A

The following compounds of Formula I were prepared by combinatorial methodology:

Example No.	Compound	MS M-H
53A	5-Bromo-3,4-difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	510
54A	N-(2,3-Dihydroxy-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	462
55A	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide	577
56A	3,4-Difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	432
57A	N-(2,3-Dihydroxy-propyl)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	444
58A	3,4-Difluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	446
59A	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	564
60A	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide	571
61A	4-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	414
62A	5-Bromo-N-(3-dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	551
63A	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	580
64A	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	501
65A	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	485

Example No.	Compound	MS M-H
66A	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide	493
67A	N-(3-Dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	473
68A	N-Benzyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	460
69A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethyl)-benzamide	384
70A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	483
71A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	495
72A	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	513
73A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thiophen-2-yl-ethyl)-benzamide	480
74A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	467
75A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-morpholin-4-yl-ethyl)-benzamide	453
76A	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide	557
77A	3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide	479
78A	2-(4-Bromo-2-methyl-phenylamino)-N-(3-dimethylamino-propyl)-3,4-difluoro-benzamide	425
79A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide	461
80A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide	475
81A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyridin-4-yl-ethyl)-benzamide	445
82A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(3-hydroxy-propyl)-benzamide	400

Example No.	Compound	MS M-H
83A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	437
84A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenethyl-benzamide	474
85A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-thiophen-2-yl-ethyl)-benzamide	450
86A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-pyridin-4-ylmethyl-benzamide	431
87A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-phenethyl-benzamide	444
88A	2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-piperidin-1-yl-ethyl)-benzamide	451
89A	5-Chloro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide	557*
90A	5-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide	541*
91A	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-pyridin-4-yl methyl-benzamide	487
92A	5-Bromo-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl- phenylamino)-benzamide	601*
93A	5-Chloro-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	486*
94A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide	497*
95A	(3-Hydroxy-pyrrolidin-1-yl)-[2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-	466
96A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	484*
97A	5-Bromo-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	530*
98A	N-[2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl]-5-chloro-2-(4-iodo-2-methyl- phenylamino)-benzamide	518*

Example No.	Compound	MS M-H
99A	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	562*
100A	[5-Bromo-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-pyrrolidin-1-yl)-	499
101A	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-benzoic acid phenethyl ester	501
102A	N-{3-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide	568*
103A	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-pyrrolidin-1-yl)-	455
104A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide	460
105A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	528*
106A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide	542*
107A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	468*
108A	5-Chloro-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	472*
109A	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	502*
110A	5-Chloro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	445*
111A	5-Chloro-N-(3-diethylamino-2-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	516*
112A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide	482*
113A	5-Bromo-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	489*
114A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	556*

Example No.	Compound	MS M-H
115A	N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	529*
116A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	500*
117A	5-Chloro-N-(3-diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	500*
118A	5-Chloro-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	514*
119A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	512*
120A	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(2-piperidin-1-yl-ethyl)-benzamide	509*
121A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperazin-1-yl-ethyl)-benzamide	544*
122A	N-(2-Diethylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	470*
123A	5-Bromo-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	516*
124A	N-(3-Hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	456*
125A	5-Fluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	429*
126A	N-(3-Diethylamino-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	484*
127A	N-(3-Diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	511*
128A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	544*
129A	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(3-piperidin-1-yl-propyl)-benzamide	523*
130A	[5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-pyrrolidin-1-yl)-	439

Example No.	Compound	MS M-H
131A	5-Bromo-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	558*
132A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide	484*
133A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide	496*
134A	[5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[4-(2-hydroxy-ethyl)-piperazin-1-	482
135A	N-(3-Diethylamino-2-hydroxy-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	500*
136A	[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoylamino]-acetic acid	443
137A	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	495*
138A	N-(3-Dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	483*
139A	N-(2-Diisopropylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	498*
140A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-phenethyl ester	490
141A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-phenethyl ester	506
142A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-benzyl ester	536
143A	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-thiobenzoic acid S-benzyl ester	503
144A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-benzyl ester	476
145A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-thiobenzoic acid S-benzyl ester	492
146A	N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	409

Example No.	Compound	MS M-H
147A	5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	429
148A	5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	413
149A	N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	475
150A	N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	593*
151A	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)-benzamide	567
152A	5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	473
153A	N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	521
154A	N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	440
155A	2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide	486
156A	5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	425
157A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	459
158A	N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	409
159A	N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	583
160A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide	538
161A	N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide	425
162A	N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	436
163A	5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	469

Example No.	Compound	MS M-H
164A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	475
165A	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide	646
166A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide	598
167A	N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	436
168A	2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)-benzamide	565
169A	N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	469
170A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide	473
171A	N-Cyclopropyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	517
172A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	519
173A	N-Benzyloxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	502
174A	N-Cyclohexyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	559
175A	N-Allyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	517
176A	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide	581
177A	2-(4-Iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-5-nitro-benzamide	500
178A	5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	567
179A	N-Cyclohexyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	451
180A	5-Chloro-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	467
181A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide	533



Example No.	Compound	MS M-H
182A	5-Bromo-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	511
183A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide	489
184A	N-Cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	478
185A	N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	538
186A	N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	477
187A	5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	431
188A	5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	475
189A	2-(4-iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide	488
190A	5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	477
191A	N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	523
192A	5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	425
193A	N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide	427
194A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	461
195A	N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	442
196A	5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide	415
197A	5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide	472
198A	N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	411

Example No.	Compound	MS M-H
199A	5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide	540
200A	N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	438
201A	N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide	411
202A	N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide	585
203A	N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide	472
204A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide	601
205A	5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide	522
206A	N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide	438

\* M+H

## EXAMPLE 207A

Preparation of [4-Chloro-2-(1H-tetrazol-5-yl)-(4-iodo-2-methyl-phenyl)-amineStep a: Preparation of 5-Chloro-2-fluoro-benzaldehyde

To a solution of 1-chloro-4-fluorobenzene (13.06 g, 0.1 mol) in THF (180 mL), at -78°C, LDA (2 M solution in THF, 50 mL, 0.1 mol) was added dropwise. After stirring at -78°C for 1.5 hours, DMF (8 mL) was added to the reaction mixture and allowed to warm up to room temperature overnight. The reaction mixture was partitioned between water and Et<sub>2</sub>O. The Et<sub>2</sub>O layer was dried (MgSO<sub>4</sub>) and the solvent removed in vacuum to give 14.95 g (94%)

10 yield of crude aldehyde:

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ, 10.3 (s, -C(=O)H).



WO 01/05392

PCT/US00/18347

of 5-(5-chloro-2-fluoro-phenyl)-1H-tetrazole: mp partial melt at 110°C,  
complete melting at 124°C);

- <sup>1</sup>H (400 Mz, CDCl<sub>3</sub>): δ 8.19-8.08 (m, 1H), 7.77-7.71 (m, 1H), 7.61-7.52 (m, 1H); <sup>13</sup>C (100 Mz, CDCl<sub>3</sub>): δ 159.00, 156.49, 140.88, 133.02, 132.93, 130.73, 129.23, 129.21, 129.08, 126.05, 118.96, 118.73, 114.50;  
5 MS (CI) M+1 = 199 (100), M = 198 (6).

Step e: Preparation of [4-Chloro-2-(1H-tetrazol-5-yl)-(4-iodo-2-methyl-phenyl)-amine

- To a solution of 2-methyl-4-iodoaniline (3.52 g, 0.0151 mol) in THF  
10 (25 mL) at -78°C, LDA (2 molar solution in THF, 11.33 mL, 0.02267 mol) was added dropwise. After stirring for 0.5 hours, a solution of 1-(tetrazol-5-yl)-2-fluoro-5-chlorobenzene (1.5 g, 0.00756 mol) in THF (15 mL) was added dropwise. The reaction was stirred for 16 hours as it warmed up to room temperature. The reaction mixture was quenched with aqueous conc. NH<sub>4</sub>Cl  
15 solution and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried (MgSO<sub>4</sub>) and the solvent removed giving a crude product as an oil. The oil with CH<sub>2</sub>Cl<sub>2</sub>->CH<sub>2</sub>Cl<sub>2</sub>:MeOH (9.7:0.3) gave 1.5 g (48%) of the desired product:  
mp 205-208; <sup>1</sup>H (400 Mz, DMSO): δ 9.13 (s, 1H), 8.00-7.99 (s, 1H), 7.69 (s, 1H), 7.55-7.52 (m, 1H), 7.43-7.40 (m, 1H), 7.12-7.05 (m, 1H), 2.24 (s, 3H);  
20 <sup>13</sup>C (100 Mz, CDCl<sub>3</sub>): δ 141.87, 139.28, 138.88, 135.47, 133.71, 131.65, 128.15, 123.69, 121.94, 116.68, 87.79, 17.22;  
MS (CI) M+2 = 413 (44), M+1 = 412 (85), M = 411 (100).  
Analysis calculated for C<sub>14</sub>H<sub>11</sub>N<sub>5</sub>Cl·0.5H<sub>2</sub>O:  
C, 39.97; H, 2.87; N, 16.65.  
25 Found: C, 38.87, H, 2.77; N, 16.47.

The following tetrazole substituted phenylamines were prepared by following the general procedure of Example 207A.

## EXAMPLE 208A

(4-Iodo-2-methyl-phenyl)-[2-(1H-tetrazol-5-yl)-phenyl]amine, mp 231°C (dec)

## EXAMPLE 209A

[4-Nitro-2-(1H-tetrazol-5-yl)-(4-iodo-2-methyl-phenyl)-amine, mp 205-208°C.

5

## EXAMPLES 210A-224A

Additional invention compounds which were prepared by the general methods described above are:

Example No.	Compound	MP °C
210A	2-(2-Chloro-4-iodo-phenylamino)-3-fluoro-4-(2-morpholin-4-yl-ethylamino)-5-nitro-benzoic acid	239-241 DEC
211A	4-Amino-2-(2-chloro-4-iodo-phenylamino)-3-fluoro-5-nitro-benzoic acid	>270
212A	2,4-Bis-(2-chloro-4-iodo-phenylamino)-3-fluoro-5-nitro-benzoic acid	>265 DEC
213A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzoic acid	218-225 DEC
214A	2-(2,6-Difluoro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid	247-249
215A	2-(2-Chloro-4-iodo-phenylamino)-4-nitro-benzoic acid	267-269
216A	2-(2,4-Diiodo-phenylamino)-4-fluoro-benzoic acid	260-261
217A	2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-benzoic acid	259-262
218A	4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid	215-217

Example No.	Compound	MP °C
219A	2-(2-Chloro-4-iodo-phenylamino)-4-fluoro- benzoic acid	242-247
220A	5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4- difluoro-benzoic acid	312.5-318
221A	2,3,5-Trifluoro-6-(4-iodo-2-methyl-phenylamino)- 4-(4-methyl-piperazin-1-yl)-benzoic acid methyl ester dihydrofluoride salt	118-121
222A	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-N-(4-methyl-piperazin-1-yl)- benazmide	214-217 DEC
223A	5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl- phenylamino)-benzoic acid N',N'-dimethyl- hydrazide	154-175 DEC
224A	4-Fluoro-2-(4-iodo-2-methyl-phenylamino)- benzoic acid hydrazide	153.5-156


## F. Other Embodiments

From the above disclosure and examples, and from the claims below, the essential features of the invention are readily apparent. The scope of the invention also encompasses various modifications and adaptations within the knowledge of a person of ordinary skill. Examples include a disclosed compound modified by addition or removal of a protecting group, or an ester, pharmaceutical salt, hydrate, acid, or amide of a disclosed compound. Publications cited herein are hereby incorporated by reference in their entirety.

What is claimed is:

## CLAIMS

1. A method for treating chronic pain, said method comprising administering to a subject in need of such treatment a composition comprising
- 5 a MEK inhibitor selected from: a compound are defined by Formula I



wherein:

R<sub>1</sub> is hydrogen, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, trifluoromethyl, or CN;

10 R<sub>2</sub> is hydrogen;

R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> independently are hydrogen, hydroxy, halo, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, nitro, CN, or (O or NH)<sub>m</sub>-(CH<sub>2</sub>)<sub>n</sub>-R<sub>9</sub>, where R<sub>9</sub> is hydrogen, hydroxy, CO<sub>2</sub>H or NR<sub>10</sub>R<sub>11</sub>;

15 n is 0 to 4;

m is 0 or 1;

R<sub>10</sub> and R<sub>11</sub> independently are hydrogen or C<sub>1</sub>-C<sub>8</sub> alkyl, or taken together with the nitrogen to which they are attached can complete a 3- to 10-member cyclic ring optionally containing

20 one, two, or three additional heteroatoms selected from O, S, NH, or N-C<sub>1</sub>-C<sub>8</sub> alkyl;

R<sub>6</sub> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C-C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, aralkyl, or

25 C<sub>3</sub>-C<sub>10</sub> cycloalkyl;



R<sub>7</sub> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl,  
C<sub>3</sub>-C<sub>10</sub> (cycloalkyl or cycloalkyl optionally containing a  
heteroatom selected from O, S, or NR<sub>9</sub>);


5 and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups can  
be unsubstituted or substituted by cycloalkyl (or cycloalkyl optionally  
containing a heteroatom selected from O, S, or NR<sub>9</sub>), aryl, aryloxy,  
heteroaryl, or heteroaryloxy; or R<sub>6</sub> and R<sub>7</sub> taken together with the  
N-O to which they are attached can complete a 5- to 10-membered  
cyclic ring, optionally containing one, two, or three additional  
10 heteroatoms selected from O, S, or NR<sub>10</sub>R<sub>11</sub>.

2. The method of claim 1, wherein said chronic pain is selected from  
neuropathic pain, idiopathic pain, and pain associated with chronic alcoholism,  
vitamin deficiency, uremia, or hypothyroidism.
3. The method of claim 2, wherein said chronic pain is a type of  
15 neuropathic pain.
4. The method of claim 3, wherein said neuropathic pain is associated  
with one of the following: inflammation, postoperative pain, phantom limb  
pain, burn pain, gout, trigeminal neuralgia, acute herpetic and postherpetic  
pain, causalgia, diabetic neuropathy, plexus avulsion, neuroma, vasculitis,  
20 viral infection, crush injury, constriction injury, tissue injury, limb amputation,  
post-operative pain, arthritis pain, and any other nerve injury between the  
peripheral nervous system and the central nervous system, inclusively.
5. The method of claim 2, wherein said chronic pain is associated with  
25 chronic alcoholism, vitamin deficiency, uremia, or hypothyroidism.
6. The method of claim 2, wherein said chronic pain is associated with  
idiopathic pain.

WO 01/05392

PCT/US00/18347

7. The method of claim 1, wherein said chronic pain is associated with inflammation.
8. The method of claim 1, wherein said chronic pain is associated with arthritis.
9. The method of claim 1, wherein said chronic pain is associated with post-operative pain.
10. The method of claim 1, wherein  $R_1$  is  $C_1$ - $C_8$  alkyl or halo.
11. The method according to claim 10 wherein  $R_6$  is hydrogen.
12. The method according to claim 11 wherein  $R_1$  is methyl.
13. The method according to claim 12 wherein the MEK inhibitor has the formula



14. The method of claim 13 wherein  $R_4$  is fluoro, and  $R_3$  and  $R_5$  are hydrogen.
15. The method of claim 14, wherein said MEK inhibitor has a structure selected from:
- 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(methoxy)-  
benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-  
benzamide;

5           4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-  
benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-  
benzamide;

10           4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-enyloxy)-  
benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-  
(cyclopropylmethoxy)-benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopentoxy)-  
benzamide;

15           4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-  
isopropyl-benzamide; and

4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-N-methyl-  
benzamide.

16.   The method of claim 13 wherein R<sub>3</sub> and R<sub>4</sub> are fluoro, and R<sub>5</sub> is  
20       hydrogen.

17.   The method of claim 16, wherein said MEK inhibitor has a structure  
selected from:

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-  
(3-furylmethoxy)-benzamide;

25           3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-ethoxy-  
benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-2-enyloxy)-  
benzamide;

30           3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropyl-  
methoxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1-methylprop-2-ynyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-phenylprop-2-ynyloxy)-benzamide;

5           3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-5-phenylpent-2-en-4-ynyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide;

10           3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(propoxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclobutyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide;

15           3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-prop-2-enyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide;

20           3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-2-enyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-3-ynyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopentyloxy)-benzamide;

25           3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-(2-fluorophenyl)-prop-2-ynyloxy)-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydropyran-2-yloxy)-benzamide;

30           3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-benzamide;

3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide; and

3,4-Difluoro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-benzamide.

5 18. The method of claim 13 wherein R<sub>3</sub> and R<sub>4</sub> are fluoro, and R<sub>5</sub> is bromo.

19. The method according to claim 18, wherein said MEK inhibitor has a structure selected from:

5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(n-propoxy)-benzamide;

5-Bromo-3,4-difluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-N-(but-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide

5-Bromo-N-butoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-but-2-enyloxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-pent-2-en-4-ynyloxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-benzyl)-N-[5-(3-methoxy-phenyl)-3-methyl-pent-2-en-4-ynyloxy]-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[3-(3-methoxy-phenyl)-prop-2-ynyloxy]-benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(thiopen-2-ylmethoxy)-benzamide;

- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(pyridin-3-ylmethoxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-(2-fluorophenyl)-prop-2-ynyloxy)-benzamide;
- 5 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(ethoxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(isopropoxy)-benzamide;
- 10 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-but-3-ynyloxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethoxy)-benzamide;
- 15 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethoxy)-benzamide;
- 5-Bromo-N-(2-diethylamino-ethoxy)-3,4-difluoro-(4-iodo-2-methyl-phenylamino)-benzamide;
- 20 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isobutoxy-benzamide;
- 5-Bromo-N-cyclohexylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 25 5-Bromo-N-cyclopentylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)-3,4-difluoro-benzamide monohydrochloride salt;
- 30 5-Bromo-N-(2-dimethylamino-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide; and

5 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide.

20. The method of claim 13 wherein R<sub>3</sub> and R<sub>4</sub> are hydrogen, and R<sub>5</sub> is halo.

21. The method according to claim 20, wherein said MEK inhibitor has a  
10 structure selected from:

5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide;

15 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide;

4-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide;


20 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide;

5-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide; and

25 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydropyran-2-yloxy)-benzamide.

22. The method of claim 12 having the formula I(A):



I(A)

23. The method of claim 22 wherein  $R_3$  and  $R_4$  are fluoro, and  $R_5$  is hydrogen.

5 24. The method according to claim 23, wherein said MEK inhibitor has selected from:

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-phenylprop-2-ynyloxy)-benzamide;

10 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-furylmethoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(but-3-ynyloxy)-benzamide;

15 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-methyl-prop-2-enyloxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(but-2-enyloxy)-benzamide;

20 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(methoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(ethoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclobutoxy)-benzamide;



3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(isopropoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide;

5           3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(n-propoxy)-benzamide;

10           3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(1-methylprop-2-ynyloxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-(3-fluorophenyl)-prop-2-ynyloxy)-benzamide;

3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(4,4-dimethylpent-2-ynyloxy)-benzamide; and

15           3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclopentoxy)-benzamide.

25. The method according to claim 1, wherein said MEK inhibitor has a structure selected from:

20           3,4,5-Trifluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Chloro-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;

25           N-Hydroxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide;

3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;

5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;

30           5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

2-(2-Fluoro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;

- 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;
- 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
- 5 2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;
- 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- 5-Bromo-2-(2-bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- 10 2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-methyl-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-5-chloro-3,4-difluoro-N-hydroxy-benzamide;
- 15 2-(2-Bromo-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;
- 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
- 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
- 20 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- 25 N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 30 5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;
- N-Cyclopropylmethoxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide;

N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

5 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

N-Cyclopropylmethoxy-2-(2-fluoro-4-iodo-phenylamino)-4-nitro-benzamide;

10 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;

5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

5-Bromo-2-(2-bromo-4-iodo-phenylamino)-N-ethoxy-3,4-difluoro-benzamide;

15 2-(2-Chloro-4-iodo-phenylamino)-N-ethoxy-4-nitro-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-5-chloro-N-cyclopropylmethoxy-3,4-difluoro-benzamide

20 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-nitro-benzamide;

N-Cyclopropylmethoxy-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

25 N-Cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

30 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide;

2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide;

N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;

5 2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide;

3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

10 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide (HCl salt);

2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide;

15 2-(2-Chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-3,4-difluoro-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-(2-dimethylamino-ethoxy)-3,4-difluoro-benzamide monohydrochloride salt;

20 5-Bromo-N-(2-dimethylamino-propoxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;


5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

25 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(tetrahydro-pyran-2-yloxy)-benzamide;

2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide; and

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide.

26. A method for treating chronic pain, said method comprising administering to a subject in need of such treatment a composition comprising a MEK inhibitor selected from: a compound of Formula I(A)



5 wherein:

R<sub>1</sub> is hydrogen, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, trifluoromethyl, or CN;

R<sub>2</sub> is hydrogen;

10 R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> independently are hydrogen, hydroxy, halo, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, nitro, CN, or -(O or NH)<sub>m</sub>-(CH<sub>2</sub>)<sub>n</sub>-R<sub>9</sub>, where R<sub>9</sub> is hydrogen, hydroxy, COOH, or NR<sub>10</sub>R<sub>11</sub>;

n is 0-4;

m is 0 or 1;

15 R<sub>10</sub> and R<sub>11</sub> independently are hydrogen or C<sub>1</sub>-C<sub>8</sub> alkyl, or taken together with the nitrogen to which they are attached can complete a 3-10 member cyclic ring optionally containing 1, 2, or 3 additional heteroatoms selected from O, S, NH, or N-C<sub>1</sub>-C<sub>8</sub> alkyl;

20 Z is COOR<sub>7</sub>, tetrazolyl, CONR<sub>6</sub>R<sub>7</sub>, CONHNR<sub>10</sub>R<sub>11</sub>, or CH<sub>2</sub>OR<sub>7</sub>;

R<sub>6</sub> and R<sub>7</sub> independently are hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl,

O

C<sub>2</sub>-C<sub>8</sub> alkynyl, C - C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, heteroaryl,

25 C<sub>3</sub>-C<sub>10</sub> cycloalkyl, or C<sub>3</sub>-C<sub>10</sub> (cycloalkyl optionally containing one, two, or three heteroatoms selected from O, S, NH, or N alkyl); or R<sub>6</sub> and R<sub>7</sub> together with the nitrogen to which they are

attached complete a 3-10 member cyclic ring optionally  
containing 1, 2, or 3 additional heteroatoms selected from O, S,  
NH, or N alkyl;

and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups can be  
5 unsubstituted or substituted by halo, hydroxy, alkoxy, amino, alkylamino,  
dialkylamino, cycloalkyl, aryl, aryloxy, heteroaryl, or heteroaryloxy, and the  
pharmaceutically acceptable salts thereof.

27. The method of claim 26, wherein said chronic pain is selected from  
10 neuropathic pain, idiopathic pain, and pain associated with chronic alcoholism,  
vitamin deficiency, uremia, or hypothyroidism.

28. The method of claim 27, wherein said chronic pain is a type of  
neuropathic pain.


29. The method of claim 28, wherein said neuropathic pain is associated  
15 with one of the following: inflammation, postoperative pain, phantom limb  
pain, burn pain, gout, trigeminal neuralgia, acute herpetic and postherpetic  
pain, causalgia, diabetic neuropathy, plexus avulsion, neuroma, vasculitis,  
viral infection, crush injury, constriction injury, tissue injury, limb amputation,  
post-operative pain, arthritis pain, and any other nerve injury between the  
20 peripheral nervous system and the central nervous system, inclusively.

30. The method of claim 27, wherein said chronic pain is associated with  
chronic alcoholism, vitamin deficiency, uremia, or hypothyroidism.

25 31. The method of claim 27, wherein said chronic pain is associated with  
idiopathic pain.

32. The method of claim 26, wherein said chronic pain is associated with  
inflammation.


33. The method of claim 26, wherein said chronic pain is associated with arthritis.
34. The method of claim 26, wherein said chronic pain is associated with post-operative pain.
35. The method of claim 26, wherein  $R_1$  is  $CH_3$  or halo.
36. The method according to claim 35 wherein Z is  $COOR_7$ , tetrazolyl, or a salt thereof.
37. The method according to claim 36, wherein said MEK inhibitor has a structure selected from:  
[4-Chloro-2-(1H-tetrazol-5-yl)-(4-iodo-2-methyl-phenyl)-amine;  
(4-Iodo-2-methyl-phenyl)-[2-(1H-tetrazol-5-yl)-phenyl]amine; and  
[4-Nitro-2-(1H-tetrazol-5-yl)-(4-iodo-2-methyl-phenyl)-amine.
38. The method according to claim 35 having the formula



39. The method of claim 38 wherein  $R_3$  is hydrogen, fluoro, or chloro;  $R_4$  is hydrogen, fluoro, chloro, or nitro; and  $R_5$  is hydrogen, chloro, fluoro, bromo, nitro, or methoxy.
40. The method of claim 39, wherein said MEK inhibitor has a structure selected from:  
4-Fluoro-2-(4-iodo-2-methylphenylamino)benzoic acid;


- 3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 5 Sodium 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoate;  
 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-benzoic acid;  
 4-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 2-(4-Iodo-2-methyl-phenylamino)-benzoic acid;  
 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 5-Iodo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 2,3,5-Trifluoro-4-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 2-(4-Iodo-phenylamino)-5-methoxy-benzoic acid;  
 5-Methyl-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
 2-(4-Iodo-2-methyl-phenylamino)-4-nitro-benzoic acid;  
 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzoic acid;  
 2,3,5-Trifluoro-6-(4-iodo-2-methyl-phenylamino)-4-(4-methyl-piperazin-  
 1-yl)-benzoic acid methyl ester dihydrofluoride salt;  
 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-methyl-piperazin-  
 1-yl)-benzamide;  
 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid N',N'-  
 dimethyl-hydrazide; and  
 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid hydrazide.

41. The method of claim 35 having the formula





42. The method of claim 41 wherein  $R_3$  is hydrogen, chloro, or fluoro;  $R_4$  is hydrogen, chloro, fluoro, or nitro;  $R_5$  is hydrogen, chloro, fluoro, bromo, nitro, or methoxy.
43. The method of claim 26, wherein said MEK inhibitor has a structure selected from:
- 2-(4-Bromo-2-methyl-phenylamino)-4-fluoro-benzoic acid;  
 2-(2-Bromo-4-iodo-phenylamino)-5-nitro-benzoic acid;  
 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-benzoic acid;  
 2-(2-Chloro-4-iodo-phenylamino)-3-fluoro-4-(2-morpholin-4-yl-ethylamino)-5-nitro-benzoic acid;  
 4-Amino-2-(2-chloro-4-iodo-phenylamino)-3-fluoro-5-nitro-benzoic acid;  
 2,4-Bis-(2-chloro-4-iodo-phenylamino)-3-fluoro-5-nitro-benzoic acid;  
 2-(2-Chloro-4-iodo-phenylamino)-4-nitro-benzoic acid;  
 2-(2,4-Diiodo-phenylamino)-4-fluoro-benzoic acid;  
 2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-benzoic acid;  
 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid;  
 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-benzoic acid; and  
 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid.
44. The method of claim 35 wherein Z is  $\text{CONR}_6\text{R}_7$ .
45. The method of claim 44 having the formula



46. The method of claim 45 wherein R<sub>3</sub> is hydrogen, chloro, or fluoro; R<sub>4</sub> is hydrogen, chloro, fluoro, or nitro; and R<sub>5</sub> is hydrogen, chloro, fluoro, bromo, nitro, or methoxy.
47. The method of claim 46, wherein said MEK inhibitor has a structure  
 5 selected from:  
 5-Chloro-N-(2-hydroxyethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide;  
 10 N-Ethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide;  
 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1H-tetrazol-5-yl)-benzamide;  
 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 15 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide;  
 [5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoylamino]-acetic acid;  
 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-propyl-benzamide;  
 5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 20 N,N-Diethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 4-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 N,N-Diethyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;  
 N-Butyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 25 5-Chloro-N,N-diethyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide;  
 5-Bromo-3,4-difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 N-(2,3-Dihydroxy-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 30 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide;

- 3,4-Difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-(2,3-Dihydroxy-propyl)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5 3,4-Difluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-10 4-yl-ethyl)-benzamide;
- 4-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-N-(3-dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 15 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-20 ethyl)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide;
- N-(3-Dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 25 N-Benzyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethyl)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
- 30 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thiophen-2-yl-ethyl)-benzamide;  
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;  
5 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-morpholin-4-yl-ethyl)-benzamide;  
5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;  
3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;  
10 2-(4-Bromo-2-methyl-phenylamino)-N-(3-dimethylamino-propyl)-3,4-difluoro-benzamide;  
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;  
15 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide;  
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyridin-4-yl-ethyl)-benzamide;  
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(3-hydroxy-propyl)-benzamide;  
20 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;  
4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenethyl-benzamide;  
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-thiophen-2-yl-ethyl)-benzamide;  
25 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-pyridin-4-ylmethyl-benzamide;  
2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-phenethyl-benzamide;  
30 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-piperidin-1-yl-ethyl)-benzamide;  
5-Chloro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;

- 5-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-pyridin-4-yl methyl-benzamide;
- 5 5-Bromo-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide;
- 10 (3-Hydroxy-pyrrolidin-1-yl)-[2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl];
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
- 15 5-Bromo-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 20 N-{3-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;
- 25 5-Bromo-2-(4-iodo-2-ethyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
- 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
- 30 5-Chloro-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;

N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-fluoro-2-(4-iodo-2-methylphenylamino)- benzamide;

5-Chloro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5 5-Chloro-N-(3-diethylamino-2-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide;

**5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide:**

5-Bromo-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-  
10 benzamide;

5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;

N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-2-(4-iodo-2-methyl-phenylamino)-5-nitro- benzamide;

15      5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-  
benzamide:

**5-Chloro-N-(3-diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide:**

20 5-Chloro-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;

**5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;**

2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(2-piperidin-1-yl-ethyl)-benzamide:

25            5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperazin-1-yl-ethyl)-  
              benzamide;

N-(2-Diethylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;

30 5-Bromo-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;

**N-(3-Hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide:**



N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;

**N-(2-Hydroxy-ethyl)-2-(4-iodo-2-ethyl-phenylamino)-5-nitro-benzamide:**

**2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-**

**benzamide:**

**5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;**

**5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-**

benzamide;

**N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;**

**N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide:**

**5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-**

**benzamide;**

**N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide:**

**N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide:**

**5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide:**

**5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-**

**benzamide;**

**5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-**

**benzamide;**

**5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-**

**benzamide;**

**N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide; 2-(4-Iodo-**

2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)-

**benzamide;**

**N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;**

**5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-**

**benzamide;**

**N-Cyclopropyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;**

**5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-**

**benzamide;**

**N-Benzyloxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;**

**N-Cyclohexyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide:**

**N-Allyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;**




- 5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide;
- 2-(4-Iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-5-nitro-benzamide;
- 5 5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
- N-Cyclohexyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide;
- 10 5-Bromo-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide;
- N-Cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
- 15 N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 20 2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide;
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
- 25 N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
- 30 N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;

- 5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;  
 N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;  
 N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;  
 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;  
 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide; and  
 N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide.

48. The method of claim 35 wherein Z is  $\text{CH}_2\text{OR}_7$ .

49. The method of claim 48 having the formula



50. The method of claim 49 wherein:  $\text{R}_3$  is hydrogen, chloro, or fluoro;  
 $\text{R}_4$  is hydrogen, chloro, fluoro, or nitro; and  $\text{R}_5$  is hydrogen, chloro, fluoro, bromo, nitro, or methoxy.
51. The method of claim 50 which is  
 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzyl alcohol;  
 [5-Chloro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol;

[2-(4-Iodo-2-methyl-phenylamino)-5-nitro-phenyl]-methanol; and  
[5-Bromo-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol.

52. The method of claim 1, wherein said MEK inhibitor has a structure  
5 selected from:

2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-  
benzamide;

N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;

10 N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-  
benzamide, potassium salt;

2-(2-Chloro-4-iodo-phenylamino)-N-cyclobutylmethoxy-3,4-difluoro-  
benzamide;

15 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-  
benzamide;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-  
benzamide;

3,4-Difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

20 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-  
benzamide;

5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-  
benzamide;

N-Cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;

25 5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-  
phenylamino)-benzamide;

5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-  
phenylamino)-benzamide;

30 5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-  
phenylamino)-benzamide;

5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-  
difluoro-benzamide;

4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;

- 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide,  
hydrochloride salt;
- 5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;
- 5 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)-  
benzamide;
- 3,4-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;
- 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-  
propoxy)-benzamide;
- 10 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-(3-hydroxy-propoxy)-  
benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-[2-(2-methoxy-  
ethoxy)-ethoxy]-benzamide;
- 15 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(3-hydroxy-propoxy)-  
benzamide;
- 5-Bromo-3,4-difluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-  
phenylamino)-benzamide;
- 3,4,5-Trifluoro-N-(3-hydroxy-propoxy)-2-(4-iodo-2-methyl-  
phenylamino)-benzamide;
- 20 3,4,5-Trifluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)-  
benzamide; and
- 25 3,4-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-  
benzamide.
53. The method of claim 1, wherein said MEK inhibitor has a structure  
selected from:
- 30 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-  
benzamide;
- N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-  
benzamide;

2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)-  
benzamide; and

3,4-Difluoro-N-(2-hydroxy-ethoxy)-2-(4-iodo-2-methyl-phenylamino)-  
benzamide.

5

54. The method of claim 26, wherein said MEK inhibitor has a structure  
selected from:

2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid;

3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

10 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-5-nitro-benzoic acid;

2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-benzoic acid;

15 7-Fluoro-6-(4-iodo-2-methyl-phenylamino)-1 *H*-benzoimidazole-5-  
carboxylic acid cyclopropylmethoxy-amide;

5-Chloro-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;  
and

5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid.

20

55. The method of claim 26, wherein said MEK inhibitor has a structure  
selected from:

2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid; and

7-Fluoro-6-(4-iodo-2-methyl-phenylamino)-1 *H*-benzoimidazole-5-  
25 carboxylic acid cyclopropylmethoxy-amide.

25

30

35

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
25 January 2001 (25.01.2001)

PCT


(10) International Publication Number  
**WO 01/05392 A2**(51) International Patent Classification<sup>7</sup>: **A61K 31/00**(74) Agents: **RYAN, M., Andrea**; Warner-Lambert Company,  
201 Tabor Road, Morris Plains, NJ 07950 et al. (US).(21) International Application Number: **PCT/US00/18347**(22) International Filing Date: **5 July 2000 (05.07.2000)**(25) Filing Language: **English**(26) Publication Language: **English**(30) Priority Data:  
**60/144,292** **16 July 1999 (16.07.1999)** **US**(71) Applicant (for all designated States except US):  
**WARNER-LAMBERT COMPANY** [US/US]; 201  
Tabor Road, Morris Plains, NJ 07950 (US).(81) Designated States (national): **AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA.**(84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**Published:**— *Without international search report and to be republished upon receipt of that report.**For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DIXON, Alistair** [GB/GB]; 108 Gwydir Street, Cambridge CB1 2LL (GB). **LEE, Kevin** [GB/GB]; 81 Williams Smith Close, Cambridge CB 9YT (GB). **PINNOCK, Robert, Denham** [GB/GB]; 3 Teasel Way, Cambridge CB1 9YT (GB).**WO 01/05392 A2**(54) Title: **METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS**


(57) Abstract: The invention features a method for treating chronic pain using a compound selected from formula (I) and formula I(A).

**FIG. 1** EFFECT OF PD 198306 ON STREPTOZOCIN-INDUCED STATIC ALLODYNIA




2/8

**FIG. 2** EFFECT OF SYSTEMIC (p.o.) ADMINISTRATION OF PD 198306 ON STREPTOZOCIN-INDUCED STATIC ALLODYNIA







**FIG. 3** EFFECT OF SYSTEMIC (p.o.) ADMINISTRATION OF PD 198306 ON CCI-INDUCED STATIC ALLODYNIA




**FIG. 4** EFFECT OF INTRATHECAL (i.t.) ADMINISTRATION OF PD 198306 ON STREPTOZOCIN-INDUCED STATIC ALLODYNIA






6/8

**FIG. 6** EFFECT OF INTRAPLANTAR (i.pl.) ADMINISTRATION OF PD 198306 ON STREPTOZOCIN-INDUCED STATIC ALLODYNIA




7/8

**FIG. 7** EFFECT OF INTRAPLANTAR (i.pl.) ADMINISTRATION OF PD 198306 ON CCI-INDUCED STATIC ALLODYNIA




**FIG. 8** EFFECT OF INTRATHECAL (i.t.) ADMINISTRATION OF PD 219622, PD 297447, PD 184352, PD 254552 OR PREGABALIN ON CCI-INDUCED STATIC ALLODYNIA



Express Mail Label No.

Page 1 of 5



Docket No.

A0000096-01-SMH

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 05 July 2000 As United States Application No. \_\_\_\_\_ or PCT International Application Number PCT/US00/18347 and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Applications

Priority Not Claimed

(Number) (Country) (Day/Month/Year Filed)



(Number) (Country) (Day/Month/Year Filed)



(Number) (Country) (Day/Month/Year Filed)



I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

<u>60/144,292</u>	<u>16 July 1999</u>
(Application Serial No.)	(Filing Date)

<u>                    </u>	<u>                    </u>
(Application Serial No.)	(Filing Date)

<u>                    </u>	<u>                    </u>
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>PCT/US00/18347</u>	<u>05 July 2000</u>	<u>Pending</u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

<u>                    </u>	<u>                    </u>	<u>                    </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

<u>                    </u>	<u>                    </u>	<u>                    </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Charles W. Ashbrook	<u>27,610</u>	Darryl C. Little	<u>40,703</u>
Heidi Berven	<u>P-48,951</u>	J. Trevor Lumb	<u>28,567</u>
Evan J. Federman	<u>37,060</u>	Claude F. Purchase	<u>47,871</u>
Mehdi Ganjeizadeh	<u>47,585</u>	James Proscia	<u>47,010</u>
Rosanne Goodman	<u>32,534</u>	Francis J. Tinney	<u>33,069</u>
Suzanne M. Harvey	<u>42,640</u>	Linda Vag	<u>32,071</u>
David R. Kurlandsky	<u>41,505</u>		

(13)

Send Correspondence to: Suzanne M. Harvey  
Warner-Lambert Company  
2800 Plymouth Road  
Ann Arbor, Michigan 48105

Direct Telephone Calls to: (name and telephone number)  
Suzanne M. Harvey, (734) 622-2658

Full name of sole or first inventor

ALISTAIR DIXON

Sole or first inventor signature

Alistair Dixon

Date 8/5/02

Residence

Cambridge, UK CB1 2LL

GBX

Citizenship

Great Britain

Post Office Address

108 Gwydir Street

Cambridge, UK CB1 2LL

Full name of sole or second inventor

Not Applicable

Sole or second inventor signature

Date

Residence

Citizenship

Post Office Address

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Charles W. Ashbrook	27,610	Darryl C. Little	40,703
Heidi Berven	P-48,951	J. Trevor Lumb	28,567
Evan J. Federman	37,060	Claude F. Purchase	47,871
Mehdi Ganjeizadeh	47,585	James Proscia	47,010
Rosanne Goodman	32,534	Francis J. Tinney	33,069
Suzanne M. Harvey	42,640	Linda Vag	32,071
David R. Kurlandsky	41,505		

Send Correspondence to: Suzanne M. Harvey  
Warner-Lambert Company  
2800 Plymouth Road  
Ann Arbor, Michigan 48105

Direct Telephone Calls to: (name and telephone number)  
Suzanne M. Harvey, (734) 622-2658

Full name of sole or first inventor

KEVIN LEE

Sole or first inventor signature

*Kevin Lee*

Date  
23/2/01

Residence

Cambridge, UK CB1 9YT <sup>KL</sup> Kenilworth, UK CV8 1DS <sup>KL</sup>

Citizenship

Great Britain

*GBX*

Post Office Address

81 William Smith Close <sup>KL</sup> 5 Archer Road <sup>KL</sup>

Cambridge, UK CB1 9YT <sup>KL</sup> Kenilworth, UK CV8 1DS <sup>KL</sup>

Full name of sole or second inventor

Not Applicable

Sole or second inventor signature

Date

Residence

Citizenship

Post Office Address

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Charles W. Ashbrook	27,610	Darryl C. Little	40,703
Heidi Berven	P-48,951	J. Trevor Lumb	28,567
Evan J. Federman	37,060	Claude F. Purchase	47,871
Mehdi Ganjeizadeh	47,585	James Proscia	47,010
Rosanne Goodman	32,534	Francis J. Tinney	33,069
Suzanne M. Harvey	42,640	Linda Vag	32,071
David R. Kurlandsky	41,505		

Send Correspondence to: Suzanne M. Harvey  
 Warner-Lambert Company  
 2800 Plymouth Road  
 Ann Arbor, Michigan 48105

Direct Telephone Calls to: (name and telephone number)  
 Suzanne M. Harvey, (734) 622-2658

3-60

Full name of sole or first inventor	
ROBERT DENHAM PINNOCK	
Sole or first inventor signature	Date
<i>Robert Denham Pinnock</i>	18th Dec 2007
Residence	
Cambridge, UK CB1 9YT	
Citizenship	
Great Britain	
Post Office Address	
3 Teasel Way	
Cambridge, UK CB1 9YT	

Full name of sole or second inventor	
Not Applicable	
Sole or second inventor signature	Date
Residence	
Citizenship	
Post Office Address	